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―Traveller, there is no path.  
The path is made by walking‖ 
 
—Antonio Machado 
 
 
 
―There are known knowns; there are things we know we know. 
We also know there are known unknowns; that is to say we know there are some things 
we do not know. 
But there are also unknown unknowns – the ones we don't know we don't know.‖ 
 
—Former United States Secretary of Defence Donald Rumsfeld 
 

  
ABSTRACT 
This thesis presents dynamic hepatocyte-specific contrast-enhanced magnetic 
resonance imaging (DHCE-MRI) as a new method for total and segmental liver 
function assessment. The method is based on the hepatocyte-specific properties of Gd-
EOB-DTPA, which is actively taken up into functioning hepatocytes. The presence of 
this substance in a tissue will induce an increase in signal intensity in magnetic 
resonance imaging (MRI). The underlying hypothesis in this work is that if the liver 
uptake of Gd-EOB-DTPA could be quantified, this would then reflect liver function. 
All studies were approved by the Stockholm Regional Ethical Review Board. The first 
study was performed on 20 healthy volunteers and showed that quantification of tracer 
uptake and liver perfusion was feasible on a segmental level using deconvolutional 
analysis (DA). In the second study, quantification of tracer uptake was done in 12 
patients with primary biliary cirrhosis (PBC) as well as in the 20 healthy controls 
examined in the first study. Both quantitative parameters derived from DA and 
traditional semi-quantitative parameters (Cmax, tmax, t1/2) were assessed. There were 
significant differences in the DA-derived parameters regarding uptake capacity and 
tracer transfer time between PBC patients and controls, but the traditional semi-
quantitative parameters were not able to separate the groups. Furthermore, there was a 
significant association between established prognostic scoring-models and the 
quantitative parameters. In the third study the healthy volunteers from the first study 
were again used as controls, but this time compared to 12 patients with primary 
sclerosing cholangitis (PSC). Total and segmental liver function as well as volume was 
assessed using DA-derived quantitative parameters, but no significant differences 
between the groups were found. A significantly more heterogeneous distribution of 
liver function was found in the PSC group, and the degree of bile duct stricturing so 
typical of PSC was found to correlate with the DA-derived liver function parameters. In 
the fourth study total and segmental liver function was assessed in 10 patients with 
varying degrees of alcohol- and/or viral-induced cirrhosis, and compared to the controls 
of the first study. Also in this patient group a significantly more heterogeneous 
distribution of liver function was found, as well as significant differences between the 
groups regarding the outcome of the functional parameters. In a simulation of a left 
hemihepatectomy, the possible implication of this heterogeneous distribution of 
function on liver resection was assessed, showing how uncertain the prediction of 
postoperative liver function can be when regional differences in liver function are not 
accounted for. In a receiver operator characteristic (ROC) analysis, the DHCE-MRI 
derived parameters showed good to excellent capacity in separating groups with normal 
or adequate liver function from patients with more severely affected liver parenchyma. 
In conclusion, DHCE-MRI can be used to assess total and segmental liver volume and 
function. Functional parameters indicative of parenchymal tracer extraction capacity, 
liver perfusion and tracer transit times can also be assessed on a global and segmental 
level. The outcome of these parameters differs significantly between patients with liver 
cirrhosis and healthy controls, and also correlates with established clinical scoring 
models. DHCE-MRI is a new and promising tool for total and segmental liver function 
assessment and deserves further studies. 
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1 INTRODUCTION 
1.1 THE EVOLUTION OF LIVER SURGERY 
In ancient Babylonian times the appearance of the liver was used to foretell the future, 
an art known as hepatoscopy. In the Bible for example, there is a passage about the 
coming Babylonian attack on Jerusalem:  
 
“For the king of Babylon will stop at the fork in the road, at the 
junction of the two roads, to seek an omen: He will cast lots with 
arrows, he will consult his idols, and he will examine the liver” 
(Ezekiel 21:20-22). 
 
In Greek mythology, two fundamentals of liver surgery are described, the first being 
the propensity of the liver parenchyma to bleed and secondly, the astonishing 
regenerative capability of the liver. As an example of the first, Homer writes in the 
Iliad: 
 
“Achilles stabbed with his sword at the liver, the liver was torn from 
its place, and from it the dark blood drenched the fold of his tunic and 
Troy’s eyes were shrouded in darkness and the light went out” 
 
Secondly, in the myth of the titan Prometheus, who was chained to Mount Caucasus by 
Zeus for giving away the knowledge of fire to the mortals, it was said that every 
morning, a giant eagle would come down to feast on his liver, only to come back for a 
new treat the next day when the liver had regenerated. 
 
In the long-lived teachings of Hippocrates and Galen, the body was thought of as a 
product of four basic substances, called the four humours. These were blood, white 
phlegm and black and yellow bile. The liver was thought of as the source of blood and 
sanguification and the yellow bile was thought of as a product of the gallbladder. It was 
not until well into the 16th century that these teachings were seriously challenged and 
replaced by the embryo of science as we know it today. In 1654 Francis Glisson 
published his works on intrahepatic vascular anatomy and the liver capsule and its 
extensions, known today as the Glissonian sheath1. During the following centuries there 
were reports of debridement of liver tissues protruding from war wounds of different 
appearances and aetiologies. Formal liver surgery was not performed until the latter 
part of the 19th century, when general anaesthesia and the understanding of aseptic 
techniques had set the stage for surgery as we know it today. The first liver resection 
with a patient surviving is attributed to Langenbuch in 1887, five years after he had 
performed the first successful cholecystectomy. He performed an operation where a 
large pedunculated tumour of the left lobe was removed 2. Liver surgery techniques 
improved during the 20th century with increasing patient survival and indications for 
surgery broadened. In 1963 Thomas Starzl performed the first human liver 
transplantation. 
 
The last few decades have seen tremendous development in the field of liver surgery. 
From being a rarely performed procedure, liver resection has become one of the most 
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frequently performed interventions in the field of surgical oncology of the upper 
gastrointestinal (GI) tract. Furthermore, surgery for primary and secondary 
malignancies in the liver nowadays probably has the best overall long-term outcome of 
all malignancies of the upper GI tract. The expansion of liver surgery is illustrated by 
Figure 1, where the number of liver resections in Sweden during the last decade is 
shown. In 1998, a total of 155 liver resections were performed in the whole country, a 
number that had risen to a total of 715 in 20093. 
 
Many factors have influenced the expansion of liver surgery, including developments 
in anaesthesia, imaging, hepatology and extended insight in liver anatomy and 
physiology. Also, better tools for surgical transection of the well-vascularized liver 
parenchyma and low central venous pressure during the parenchymal transection have 
led to less intraoperative haemorrhage, and mortality in liver resection for colorectal 
cancer liver metastases is now below 1% in specialized units4, 5. The key factor behind 
this unparalleled expansion is undoubtedly the insight that long-term survival and even 
cure can be achieved by the complete surgical removal of liver metastases from 
colorectal cancer, and to some extent, even from metastases of other origin. In parts of 
the world, the effects of endemic hepatitis B and C in the population are reflected in the 
high prevalence of liver cirrhosis and hepatocellular carcinoma (HCC), making this 
disease the fifth most common cancer in the world. Only surgical intervention or 
transplantation offer a chance of cure for HCC. 
 
Today the art of hepatoscopy has been largely abandoned and the source of disease is 
seldom attributed to dyscrasia of the four humours, but the liver parenchyma continues 
to challenge scientists, hepatologists and surgeons with its multitude of functions, its 
remarkable regenerative capacity and the technical challenges it poses for the surgeon 
who dares enter its realm. 
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1.2 CURRENT ISSUES IN LIVER SURGERY AND HEPATOLOGY 
The fields of hepatology and liver surgery are developing rapidly. There are, however, 
some issues of particular interest seen in the context of this thesis. 
 
Despite the tremendous advances regarding the understanding of liver function and 
physiology together with an almost unforeseen development in the field of medical 
imaging, postoperative liver failure remains a serious problem. It significantly 
contributes to postoperative morbidity and is the major cause of mortality after liver 
resection 6, 7. 
 
Liver surgery in the cirrhotic liver poses its particular challenges regarding the selection 
of patients suitable for surgical treatment. The challenge is to not submit patients to 
surgery that will succumb to liver failure, nor denying patients the chance of cure just 
from the notion that their liver function is not sufficient to survive the surgery. 
 
In hepatology, dealing with autoimmune and cholestatic diseases such as primary 
biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) poses its particular 
challenges. Staging of disease, sampling error in liver biopsy, predicting outcome for 
the individual patient, choosing the right time for endoscopic intervention, evaluation of 
the effects of medical or endoscopic treatments and finding the optimal time point for 
liver transplantation are just some of the problems facing the hepatologists dealing with 
these diseases. 
 
1.3 LIVER ANATOMY AND PHYSIOLOGY 
1.3.1 Embryology 
Embryologically, the liver originates as a bud of cells in the ventral mesentery of the 
foregut, invading the left and right vitelline veins. The bud develops into the liver and 
portions of the vitelline veins later become the vena cava, the right hepatic vein and the 
portal vein. The middle and left hepatic veins do not originate directly from the original 
vitelline veins, but from consolidation of small veins formed in the liver as it grows. In 
foetal life, placental blood is shunted through the liver by the left umbilical vein to a 
portion of the left portal vein wherefrom it proceeds via the ductus venosus to the 
inferior vena cava (IVC) just inferior to the heart. After birth the foetal circulation 
changes and the ductus venosus involutes to a fibrotic band, the ligamentum venosum. 
It stretches between the portion of the left portal vein known as the umbilical part of the 
portal vein and the IVC. The umbilical vein becomes the round ligament, or 
ligamentum teres, in the falciform ligament. These embryological characteristics are 
important for the understanding of the intrinsic right and left division of the liver, as 
well as of the non-symmetric branching of the left portal vein.  
 
1.3.2 A brief history of the understanding of hepatic anatomy 
Already in ancient times, liver anatomy was described by the lobular arrangement of 
the parenchyma, using surface markings and obvious external landmarks, for example 
the falciform ligament, the umbilical fissure and the ligamentum venosum for the 
traditional division of the liver into the right and left lobes. The quadrate lobe and the 
caudate lobe were also described according to their anatomical landmarks. Historically 
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this was the prevailing system to describe the liver for centuries, and is still used for 
morphologic description of liver anatomy. It was not until the end of the 19th century 
with the works of Cantlie and Rex that the internal arrangement of the hepatic 
structures was used to describe the complex functional liver anatomy8, 9. Using 
injection die-casts they discovered the portal vascular watershed that divides the liver 
into the right and left sides. This watershed follows what is today known as the Cantlie 
line, which is actually a three-dimensional plane going from the gallbladder fossa down 
to the IVC, dividing the liver into the left and right hemilivers. This seminal work was 
followed by several important studies, for example by the Swedish anatomist Hjortsjö 
who contributed significantly to the understanding of intrahepatic biliary anatomy 10. 
The works of Healey and Schroy further broadened the understanding of the 
intrahepatic biliary and arterial vascular anatomy, and they suggested a subdivision of 
the liver on three levels based on the arterial and biliary anatomy11, 12. The French 
surgeon-anatomist Couinaud suggested a similar three-levelled subdivision of the liver 
based on the portal vein divisions13. He introduced the segmental division of the liver as 
we know it today, numbering the segments after the arrangements of the 
arrondissements of Paris, with a total of 8 liver segments as illustrated in Figure 2b. 
 
 
The many ways of dividing the liver into lobes, sectors, areas, segments, sections etc. 
based on different anatomical structures led to a significant confusion regarding the 
nomenclature of hepatic anatomy and also hepatic resections 14. In an effort to 
overcome this ―hepatic babel‖, the Brisbane 2000 system of nomenclature of hepatic 
anatomy and resection was introduced by the International Hepato-Pancreato-Biliary 
Association (IHPBA) 15. In this system, the first order of division is into the left and 
right hemilivers, the second order divides the right hemiliver into the right anterior and 
posterior sections, and the left hemiliver into the left medial and left lateral sections. 
The third order division is into the segments that are similar to the ones described and 
numbered by Couinaud. In the left hemiliver the lateral section consists of segments 2 
and 3, and the medial section consists of segment 4 (often subdivided into segment 4a 
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and 4b). In the right hemiliver the anterior section consists of segments 5 and 8, and the 
posterior section consists of segments 6 and 7. Segment 1 corresponds to the caudate 
lobe and is not part of the three-levelled division described above due to the separate 
and unique vascular supply, biliary drainage and vascular outflow of this segment 16. 
An overview of the morphologic and functional division of liver anatomy is presented 
in Figure 2. 
 
1.3.3 Anatomy 
1.3.3.1 Surface anatomy 
The liver is one of the largest organs of the body, located in the right upper quadrant of 
the abdomen contributing about 2-3% to the total body weight17. The lobular 
morphologic arrangement is described above in Figure 2a. The liver is partially covered 
by peritoneum and attached to the abdominal wall and diaphragm by reflections of 
these peritoneal coverings. At the cranio-dorsal aspect of the liver along the 
diaphragmatic surface, there is an area devoid of peritoneal covering referred to as the 
bare area or area nuda. The peritoneal reflections, somewhat erroneously referred to as 
ligaments, are divided into the left and right coronary and triangular ligaments. The 
falciform ligament originates close to the umbilicus and stretches towards the liver, 
going down to the exit point of the hepatic veins. The falciform ligament contains in its 
dorsal part the ligamentum teres previously mentioned. In liver surgery the liver often 
has to be mobilized by division of these peritoneal avascular folds. The liver is closely 
related to several organs in the upper abdominal cavity. The lesser curvature of the 
stomach is attached to the left liver by the lesser omentum, in the cranial part known as 
the gastrohepatic ligament, and in its caudal part it becomes the hepatoduodenal 
ligament that connects the pyloric region of the stomach and proximal part of the 
duodenum to the liver hilum. The ligament contains structures of utmost importance to 
liver surgery: the common bile duct, the hepatic artery and the main trunc of the portal 
vein. The right colonic flexure has a close relationship with the right liver, as does the 
right kidney and adrenal gland. 
 
1.3.3.2 Vascular anatomy 
The liver has a unique dual vascular supply with the portal vein contributing 
approximately 75% of the inflow and the hepatic artery with branches approximately 
25%18, 19. The arterial anatomy of the liver is variable, but most commonly the hepatic 
artery originates from the celiac trunc together with the splenic and left gastric arteries, 
a pattern recognized in about 90% of patients studied 20. The common hepatic artery 
usually has a suprapancreatic course as it traverses towards the hepatoduodenal 
ligament where it divides into the proper hepatic artery and the gastroduodenal artery. 
The proper hepatic artery then continues towards the liver in the antero-medial aspect 
of the hepatoduodenal ligament where it, usually close to the liver hilum, divides into 
the right and left hepatic arteries. Most commonly, the cystic artery arises from the 
right hepatic artery. Common variations to this pattern is a right hepatic artery 
branching from the superior mesenteric artery (approximately 10%) and an accessory 
or replaced left hepatic artery branching off from the left gastric artery (approximately 
10%), running through the lesser omentum to supply the left part of the liver. More 
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uncommon variations (1-2%) include a completely replaced hepatic artery originating 
from the superior mesenteric artery or directly from the aorta21. 
 
The portal vein is formed by the confluence of the superior mesenteric vein and the 
splenic vein behind the neck of the pancreas. Other tributaries to the portal vein include 
the coronary or left gastric vein and the cystic veins from the gallbladder. The common 
trunc of the portal vein is located in the posterior aspect of the hepatoduodenal ligament 
and close to the liver hilum divides into the left and right portal veins. Often there is a 
branch to the caudate lobe from the portal vein at the hilar level. The right portal vein 
has a short intrahepatic course before it divides into the anterior and posterior branches 
to segments 5, 8 and 6, 7 respectively. Due to the embryologic origin of the left portal 
vein, it is somewhat different in its distribution. It often has a relatively long 
extrahepatic, transverse portion and enters the parenchyma as it approaches the 
umbilical fissure as the umbilical portion of the left portal vein14, 22. The venous 
drainage of liver blood is mainly from the three hepatic veins that drain into the IVC 
just below the diaphragm. The three hepatic veins are of different embryologic origin as 
previously mentioned. Often the left and middle hepatic veins coalesce into a common 
trunc before draining into the IVC. The right hepatic vein is usually of a larger diameter 
with a short extrahepatic course. In addition to the three main hepatic veins there is 
sometimes an accessory hepatic vein on the right side draining into the IVC inferior to 
the main trunc of the right hepatic vein. There are also regularly several bridging veins 
from the right-sided segments and segment 1 that drain directly into the IVC 22. These 
bridging veins need to be handled carefully when mobilizing the liver to avoid profuse 
haemorrhage. 
 
1.3.3.3 Bile duct anatomy  
The bile is transported out of the liver by ducts that are formed by the successive 
joining of small bile canaliculi and ducts into consecutively larger structures, 
culminating in the common bile duct. Typically, the ducts from the anterior and 
posterior section of the right hemiliver join to form the right hepatic duct that after a 
short extrahepatic course joins with the left hepatic duct. There are significant 
anatomical variations regarding the branching of the right duct that are of great 
importance in liver and biliary surgery 23. The left hepatic duct drains the left hemiliver 
and has less anatomical variations, as it runs along with the transverse part of the left 
portal vein. The left and right hepatic ducts join in the hilar part of the hepatoduodenal 
ligament to form the common hepatic duct (CHD). The CHD is located in the 
anterolateral part of the hepatoduodenal ligament where it is joined by the cystic duct. 
After the cystic duct junction, the CHD becomes the common bile duct (CBD). There 
are also significant variations in the way the cystic duct and the CHD junction, and 
knowledge of and respect for the complexity of the biliary anatomy is prudent when 
performing any hepatobiliary surgery, even cholecystectomies. 
 
1.3.4 Liver physiology 
In 1855, the famous French physiologist and scientist Claude Bernard stated: ―The liver 
is too large to produce only bile‖ 24. Time would prove him right, and today we know 
that the liver is an organ responsible for a multitude of complex cellular activities, some 
of them being storage of glycogen, synthesis of amino acids, albumin and coagulation 
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factors, detoxification of drugs and endotoxins as well as excretion of bile. The liver 
also plays a major role in glucose homeostasis through gluconeogenesis and 
glycogenolysis. These cellular activities are dependent on an adequate blood supply and 
venous drainage, but also on the integrity of the bile ducts ensuring adequate outflow of 
the bile. 
 
The liver consists mainly of specialized liver cells, hepatocytes, which comprise about 
60% of the liver mass. Other cells found in the liver are the endothelial cells lining the 
sinusoids of the liver, the epithelial 
cells of the bile ducts known as 
cholangiocytes, the phagocytic 
Kupffer-cells of the reticulo-
endothelial system (RES) and the 
hepatic stellate cells, also known 
as Ito-cells or lipocytes 25. The 
basic cellular architecture of the 
liver is often referred to as the 
hepatic lobule shown in Figure 3. 
The lobule is usually described as 
a hexagonal structure with a 
central vein in the middle. The 
central veins of the lobules 
eventually coalesce into the 
draining hepatic veins. The central 
vein is connected to the portal 
inflow by liver sinusoidal veins 
lined by endothelial cells with 
hepatocytes arranged in a 
columnar fashion. The space 
between the sinusoidal cells and 
the hepatocytes is known as the 
space of Disse. This is where the 
hepatic stellate cells are usually 
found, as shown in Figure 4. The 
terminal portions of the portal vein together with hepatic artery branches, arterioles, and 
bile ducts form the portal triads, also known as portal tracts. The hepatic arterioles are 
the main supplier of oxygenated blood to the bile ducts. A portion of the arterial 
oxygenated blood also blends with portal blood in the terminal portal branches draining 
into the sinusoidal veins illustrated in Figure 326. The functional arrangement of the 
liver parenchyma is perhaps better described by the hepatic acinus also shown in Figure 
327. The acinus is oriented around the afferent vessels of the liver, and roughly divided 
into three zones with increasing distance from the oxygen- and nutrient-rich afferent 
vessels. The more peripheral hepatocytes receive less oxygenated blood, and the more 
centrally located cells are the first to be exposed to blood-borne toxins. This 
arrangement leads to certain disease-specific pathological processes that will affect the 
different zones in specific ways, and functionally, the hepatocytes of the three zones 
have slightly different function and different expression of enzymes28. 
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1.4 LIVER DISEASE 
Liver cirrhosis is not a distinct disease entity, but rather the result of longstanding 
parenchymal injury, with a wide range of possible aetiologies. For example, the injury 
could be due to chronic toxic exposure of the liver, such as in excessive alcohol intake, 
chronic inflammation as seen in chronic viral hepatitis or chronic cholestatic diseases, 
such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Other 
forms of chronic liver disease are the non-alcoholic fatty liver disease (NAFLD) and 
non-alcoholic steatohepatitis (NASH), closely related to the metabolic syndrome and 
seen in increasing numbers in the Western world29. The hepatic stellate cells are 
proposed to play a key role in the process from inflammation to fibrosis and ultimately 
to liver cirrhosis. The stellate cell is activated by inflammatory cytokines and in its 
activated state produces collagen that is deposited in the space of Disse, thereby 
increasing portal pressure, and the production of matrix degrading proteins is 
diminished, thereby tipping the balance of collagen formation and degradation towards 
increasing matrix buildup30. As fibrosis continues, functioning hepatic parenchyma is 
replaced by connective tissue, and the functional capacity of the liver is gradually 
impaired. The degree of fibrosis is often scored according to the system proposed by 
Batts and Ludwig as outlined in Table 131. Other systems, such as the Metavir score, 
also assess the disease activity in chronic hepatitis for grading of liver disease32. The 
degree of fibrosis and cirrhosis is often not uniformly distributed within the liver and 
significantly differing results can be obtained from random liver biopsies. In a study of 
124 patients with chronic hepatitis C, laparoscopic biopsies from the left and right liver 
were obtained simultaneously and in 14.5% cirrhosis was diagnosed in one side but not 
the other33. In another study on patients with fatty liver disease undergoing paired 
biopsies, 35% of the patients had bridging fibrosis in one biopsy, but no or only mild 
fibrosis in the other34. This uneven distribution of disease leads to significant sampling 
error and possible under-staging of disease grade when liver biopsies are used to grade 
or stage chronic liver disease35. Liver fibrosis has been shown to be a reversible 
condition, whereas cirrhosis is not. 
 
Table 1: Fibrosis scoring system according to Batts and Ludwig31 
Stage 0 No fibrosis 
Stage 1 Portal fibrosis (fibrosis in the portal triads, but not outside of these) 
Stage 2 Periportal fibrosis (fibrosis extending into the periportal space) 
Stage 3 Septal or bridging fibrosis (portal triads linked by fibrotic septa) 
Stage 4 Cirrhosis 
  
In its late stages, liver cirrhosis is characterized by progressive and sometimes rapid 
liver failure with portal hypertension, ascites, hepatic encephalopathy and significantly 
increased mortality. In addition, liver cirrhosis is also identified as a major risk factor 
for the development of HCC. Liver cirrhosis is also known to induce changes in the 
relative distribution of liver volume between the right and left hemilivers. Often a 
relative hypotrophy of the right liver is noted with a simultaneous relative hypertrophy 
of the caudate lobe and left hemiliver36-39. 
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1.4.1 Primary biliary cirrhosis 
Primary biliary cirrhosis (PBC) is an autoimmune chronic inflammatory disease 
characterized by progressive destruction of intrahepatic bile ducts, resulting in 
cholestasis, portal inflammation and fibrosis which eventually may lead to cirrhosis and 
liver failure40. The exact aetiology is unknown, but the disease seems to affect patients 
with a genetic predisposition and as in many other autoimmune diseases, there is a 
female predominance. In PBC, 9 out of 10 patients are female with the typical patient 
being a woman in her fifties40-42. PBC is a fairly uncommon disease with prevalence 
rates ranging from 0.7 to 40/100 000 in epidemiological studies43, 44. The disease 
usually presents with pruritus followed by jaundice and hepato- and splenomegaly, 
although with increasing use of serum liver function tests in routine practice, more 
patients are diagnosed at an early asymptomatic stage. A pronounced fatigue is a 
common finding in affected individuals, and is sometimes the first symptom of the 
disease45. Diagnosis is based on the presence of anti-mitochondrial antibodies (AMA) 
and elevation of biochemical markers of cholestasis, especially alkaline phosphatase 
(ALP). If both AMA is present and ALP is elevated for a period longer than 6 months, 
it is highly suggestive of a PBC diagnosis46. Liver biopsy is no longer mandatory for 
diagnosis, but aids in the work-up of patients by excluding other causes of cholestasis47. 
Furthermore, it may give useful information on disease activity and stage46. The disease 
does not affect the liver uniformly and as in cirrhosis in general, there is a considerable 
risk of under-staging on single liver biopsies48. Natural history is variable and ranges 
from stable to rapidly progressive disease. Various attempts have been made to predict 
the unpredictable clinical course of patients with PBC and several prognostic models 
have been developed to predict survival49-53. Of these models, the Mayo updated natural 
history model for primary biliary cirrhosis is probably the most widely used. It is based 
on a Cox proportional hazards model where the regression coefficients for age, serum 
albumin, bilirubin and prothrombin time in combination with the dichotomous 
variables oedema and diuretic therapy are used to calculate the short-term survival 
probability54. There is no curative medical treatment for PBC, but liver transplantation 
is an option in late stages of the disease. Treatment with ursodeoxycholic acid has been 
shown to improve symptoms, biochemical status and time to liver transplantation, but 
results regarding its effect on overall survival are contradictory55. Patients with PBC 
have an increased risk for developing HCC, and regular ultrasound screening is 
recommended56. 
 
1.4.2 Primary sclerosing cholangitis 
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease characterized 
by progressive obliterating fibrosis of the intra- and extra-hepatic bile ducts, ultimately 
leading to liver cirrhosis. The aetiology is largely unknown, but a close association with 
inflammatory bowel disease, especially ulcerative colitis, has been described. There is a 
male predominance and the prevalence is approximately 10/100 000 with a clear 
geographic variability57. The diagnosis is based on typical findings on magnetic 
resonance cholangiography (MRC) or endoscopic retrograde cholangiography (ERC) 
with beading and strictures seen in the biliary tree46. Liver biopsy is not mandatory for 
diagnosis, but is not infrequently performed in clinical practice, often to rule out 
overlap between PSC and autoimmune hepatitis (AIH)46. The disease does not affect 
the liver homogeneously and in cases where liver biopsy is deemed necessary, the use 
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of paired biopsies has been advised58. There is no effective medical treatment or cure 
for PSC. Ursodeoxycholic acid has been used, but the results are contradicting57. Liver 
transplantation is an alternative in advanced disease, but relapse in the transplanted 
liver is noted in as much as 20% after five years59. Palliation of symptoms such as 
pruritus and perhaps even prolonged survival can be achieved with endoscopic 
dilatation of dominant bile duct strictures57, 59. Defining which biliary strictures are 
significant, not only as radiologically dominant, but functionally in terms of bile flow 
obstruction poses a clinical challenge. Although the clinical course in the individual 
patient is notoriously hard to predict, most patients will be either dead or subject to 
liver transplantation within 12-17 years from time of diagnosis60. On a group level, 
short-term mortality can be predicted using the revised natural history model for PSC, 
also known as the Mayo risk score61. Like the PBC model, this score is based on the 
regression coefficients from a Cox proportional hazards model, using the parameters 
age, bilirubin, albumin, aspartate transaminase (AST) and the dichotomous variable 
history of variceal bleed. Patients with PSC are at high risk of developing 
cholangiocarcinoma and gallbladder cancer, and regular ultrasound screening is 
advocated46.  
 
1.4.3 Alcohol- and viral-induced liver cirrhosis 
Worldwide, the burden of disease inflicted by hepatitis B virus (HBV) and hepatitis C 
virus (HCV) infection is staggering, accounting for almost 1 million deaths annually. 
Approximately half of this mortality has been attributed to liver failure and the other 
half to death from HCC62. Even though the incidence of new cases of HCV infection is 
declining, the number of patients with longstanding infection is still growing, and the 
peak regarding morbidity due to HCV infection is probably still to come63. 
Approximately one third of infected patients will develop severe liver disease 
(advanced fibrosis, cirrhosis or HCC) after 30 years of infection64. Cirrhosis in itself is 
a risk factor for developing HCC, but this is even more pronounced in HBV and HCV 
infection, with a yearly incidence of HCC as high as 8% in patients with HCV and 
established cirrhosis56. It is therefore suggested that patients diagnosed with HBV or 
HCV infection should regularly be screened for HCC, since diagnosis at an earlier stage 
is associated with better survival56. In northern Europe, where HBV and HCV infection 
is not as prevalent, alcohol has been identified as the leading cause of liver cirrhosis, 
with more than 60% of cirrhosis cases in Sweden being attributed to overconsumption 
of alcohol65. Overconsumption of alcohol in combination with HCV infection has been 
shown to be especially deleterious for the liver parenchyma, and accelerates the 
progression of fibrosis to cirrhosis66. 
 
1.5 EVALUATION OF LIVER FUNCTION 
As previously mentioned, the liver has a multitude of complex cellular functions with 
numerous enzyme systems involved. It is futile to think that one single test, no matter 
how elaborate, could reflect the true functional status of all enzyme systems of this 
complex organ. Also previously mentioned, liver biopsy can assess the degree of 
fibrosis and parenchymal inflammation, but with a significant risk of sampling error. 
Furthermore, liver biopsy is invasive and associated with complications and even 
mortality67. Several inherently different methods to evaluate liver function non-
invasively have been developed, including biochemical serum liver function tests, tests 
   11 
of metabolic functional capacity, clearance tests, imaging-based liver function 
assessment and scoring models. The most important and frequently used methods are 
described in further detail below. The rationale to evaluate liver function can be to stage 
liver disease, prognosticate outcome for a patient or a group of patients or to 
preoperatively estimate total liver function and predict the postoperative remnant liver 
function, with the aim to avoid postoperative liver failure or death. 
 
1.5.1 Serum liver function tests 
A wide range of biochemical tests derived from serum are used to assess different 
aspects of liver function, generally being referred to as liver function tests or LFTs. 
Serum LFTs are usually readily available and inexpensive. However, results must be 
interpreted with caution and LFTs only give indirect information about the functional 
capacity of the liver parenchyma, including cellular injury, synthetic capacity and 
excretory function. Furthermore, serum levels of the most frequently used LFTs are 
non-specific and influenced by factors other than liver function. AST and alanine 
aminotransferase (ALT) can be used to assess ongoing hepatocyte injury and necrosis, 
but give limited information about the extent or severity of cell death68. The serum 
levels of ALP and γ-glutamyltransferase (GGT) usually rise in cases of cholestasis, but 
increased levels of ALP can also originate from bone and bowel. An isolated elevation 
of GGT can be indicative of alcohol abuse. Serum albumin and prothrombin time can 
be used to assess the synthetic capacity of the liver, but decreased levels of serum 
albumin can be noted in diseases associated with protein loss and inflammatory 
conditions. Elevated levels of unconjugated bilirubin are indicative of impaired 
transport into hepatocytes or decreased conjugation ability in the hepatocyte, but can 
also be seen in conditions with increased production of bilirubin such as hemolysis. 
Increased levels of conjugated bilirubin are seen in diseases associated with intra- or 
extrahepatic cholestasis69. An elevated ALP is usually seen together with increased 
serum bilirubin in cases with extrahepatic cholestasis70.  
 
1.5.2 Scoring models 
Serum LFTs alone are not sufficient to stage liver disease, determine its prognosis or to 
preoperatively assess liver function. LFTs become more applicable when used in 
combination in scoring models such as the Mayo risk score models used in PBC and 
PSC, as well as other commonly used scoring models including the Child-Pugh score 
(CPS) and the Model for End-stage Liver Disease (MELD). 
 
1.5.2.1 Child-Pugh Score 
The CPS system (sometimes referred to as Child-Turcotte-Pugh score (CTPS)) was 
first proposed in 1964 by Child and Turcotte as a way to predict mortality after porto-
caval shunt surgery68. It was modified by Pugh in 1973 in order to predict operative 
mortality and long-term outcome after surgery for oesophageal varices71, 72. The CPS as 
it is used today is made up of five variables, two of them being subjective (ascites and 
encephalopathy) and the other three objective LFTs. The variables used and the points 
attributed to them are displayed in Table 2. 
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The total score obtained will stratify a patient into one of three groups, known as Child-
Pugh class (CPC). A total score of 5-6 will put a patient in CPC A, a total score of 7-9 
will correspond to CPC B and a score of 10 or more (maximum 15) is equivalent to  
 
CPC C. Although this scoring model was originally intended for surgical 
prognostication, it has gained widespread use in hepatology to predict long-term 
survival and in surgery to stratify patients in risk groups regarding risk of surgical 
mortality as summarized in Table 3. In a review of 118 studies CPC was found to be 
the most consistent and robust predictor of mortality in liver cirrhosis73. It has also been 
shown that CPC predicts mortality and morbidity after liver resection. In general, only 
patients with CPC A without signs of portal hypertension are candidates for major liver 
resection74. 
 
Table 3: Mortality risk in cirrhosis according to CPC 
CPC 1-year survival 2-year survival Surgical mortality(*
75) 
A 95% 90% 10% 
B 80% 70% 30% 
C 45% 38% 82% 
(*various abdominal operations, both elective and emergency procedures) 
 
An advantage with the CPS/CPC is its ease of use and it is easily calculated bedside. 
The CPS model has been challenged, mainly on the basis of its use of the two 
subjective parameters, rendering it vulnerable to observer bias, and also due to the 
―floor‖ and ―ceiling‖ effects inherent in the model76. For example, a patient with 
bilirubin of 51 µmol/L receives the same score as a patient with bilirubin levels at 300 
µmol/L. Furthermore, the scoring model fails in separating patients with CPC A that 
are at high risk for complications, from those with a probable favourable surgical 
outcome. It is also without predictive value in chronic liver disease without established 
cirrhosis. 
 
1.5.2.2 MELD 
The MELD-score originated from an attempt to predict short-term results after 
transjugular intrahepatic porto-systemic shunt (TIPS) procedures77. It was later slightly 
modified and in its current form the MELD-score contains the variables bilirubin, 
creatinine and PK-INR, and is calculated by the formula: 
 
Table 2: The Child-Pugh scoring system72 
Points 1 2 3 
Ascites None Mild Severe 
Encephalopathy None Grade I-II Grade III-IV 
Albumin (g/L) >35 28-35 <28 
Bilirubin 
(µmol/L) <35 35-51 >51 
PK-INR <1.7 1.7-2.3 >2.3 
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                                                                , 
 
with bilirubin and creatinine measured in mg/L78. The MELD-score is predominantly 
used for prioritizing patients on the waiting-list for liver transplantation, since it has 
been shown to accurately predict the 3-month mortality76, 79. Allocating organs 
depending on the patient’s MELD-score rather than waiting time has been shown to 
improve results after liver transplantation80. The MELD-score can also predict 
mortality after liver surgery. In a retrospective study on 82 patients with cirrhosis 
undergoing liver resection for HCC, it was found that a MELD-score above 8 was 
associated with a 29% mortality rate, compared to 0% if the MELD-score was 8 or 
less81. Another retrospective study on 154 cirrhotic patients resected for HCC found 
that if the MELD-score was above 11, there was a high risk of postoperative liver 
failure, and serious morbidity was seen in patients with a MELD-score ≥ 982. The 
MELD-score has shown no benefit in predicting outcome in patients without 
cirrhosis83.  
 
1.5.3 Quantitative measurement of hepatic uptake, metabolism and 
elimination capacity 
Quantitative estimations of the functional status of one or several liver enzyme systems 
can be obtained by the measurement of the metabolism or elimination of substances 
that are solely metabolized or eliminated by the liver. A vast number of such tests have 
been described in the literature, but few are routinely used in clinical practice84-86. The 
more frequently used or studied tests are summarized below. 
 
1.5.3.1 MEGX 
The MEGX-test (monoethylglycinexylidide) uses the conversion of lidocaine to 
MEGX by the cytochrome p450 system87. After intravenous administration of 
lidocaine, the serum levels of MEGX are usually assessed 15 minutes later, although 
other time-spans have also been used. Decreased levels of MEGX are found in patients 
with liver cirrhosis, and serum levels <15 ng/mL have been shown to be associated 
with an increased complication rate after liver surgery88. 
 
1.5.3.2 Galactose elimination capacity 
The activity of the intracellular hepatic enzyme galactokinase can be assessed by the 
galactose elimination capacity (GEC) of the liver89. Galactose is administered 
intravenously, followed by repetitive blood and urine sampling. Decreased elimination 
rates have been shown to be associated with poorer outcome after liver surgery90, 91. 
 
1.5.3.3 Aminopyrine breath test 
After intravenous administration of 14C-labeled aminopyrine, the test relies on the 
demethylation and metabolism of the substance that will result in the production of 
radioactive 14CO2, which can be measured in the exhaled air. The test provides 
information on the cytochrome p450 enzyme system, and reduced levels are seen in 
patients with liver cirrhosis when compared to normal controls92. The test has been 
shown to predict survival in cirrhosis, but was not proven to be superior to the CPS in 
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this setting93. The test is time-consuming and results are influenced by factors other 
than liver function that induce the cytochrome p450 system. 
 
1.5.3.4 Indocyanine green clearance 
Indocyanine green is an organic anionic dye that is exclusively taken up into the 
hepatocytes through a carrier-mediated system similar to the transport mechanisms of 
other organic anions and bile. It has been shown that the organic anion transporting 
polypeptides (OATP), specifically the OATP1B3, and Na+-taurocholate cotransporting 
polypeptide (NTCP) are involved in this transmembranous transport94. ICG is rapidly 
extracted from the blood-stream at a rate that is highly dependent on hepatic blood 
flow, and then excreted in an unchanged form into the bile through an ATP-dependent 
transport system95. The clearance of ICG is thus dependent on hepatic blood flow, the 
functioning hepatocyte mass and the energy status of the liver. The elimination capacity 
has been described using a multitude of units, amongst them the retention rate after 15 
minutes (ICG R15 (%)), the plasma disappearance rate (ICG PDR (%/min)) or ICG 
clearance (ICG CL (ml kg-1min-1))85. The standard procedure for ICG clearance 
involves intravenous administration of the dye, with either repetitive blood sampling or 
transcutaneous pulse dye densitometry to assess the serum levels of ICG at time-points 
dependent on how elimination is reported95-97. The ICG elimination capacity is 
probably the most widely used and studied dynamic test method to quantitatively assess 
liver function, with several studies showing efficacy in terms of preoperative evaluation 
of liver function and prediction of postoperative morbidity and mortality98. A safety 
limit of ICG R15 of 14% was found by Fan et al in a study on 54 patients with cirrhosis 
and HCC undergoing resection of at least two liver segments99. In a study on 127 
patients with liver cirrhosis undergoing surgery for HCC, Lau et al also found that the 
safety limit for major resection was an ICG R15 of 14%. However, minor resections 
were feasible up to an ICG R15 of 23%100. A decision algorithm for liver resections in 
patients with cirrhosis has been proposed by Makuuchi et al, with the extent of 
resection being dependent on ICG R15101. Using this algorithm, Imamura et al 
presented a series of 1056 liver resections with no mortality102. ICG elimination as a 
liver function test has been questioned on the basis of its high dependency on liver 
perfusion and perhaps being less dependent on actual hepatocyte function. It has also 
been criticized for failing to show a substantial advantage for predicting outcome 
compared to Child-Pugh score alone86. Also, a significant overlap in ICG PDR between 
healthy controls and patients with impaired liver function has been shown96. The most 
frequent clinical use of ICG clearance for preoperative liver function assessment is seen 
in Asian centres, and less so in Europe and USA103. 
 
1.5.3.5 LiMax 
The LiMax test is based on the liver conversion capacity of 13C-labeled methacetin to 
paracetamol and 13CO2 by the cytochrome p450 isoenzyme CYP1A2104. This enzyme is 
found only in hepatocytes, is not induced by drugs or other substances and does not 
have significant genetic variations105. The metabolite 13CO2 can be continuously 
measured (in µg/kg/h) bedside in the exhaled air, and levels reflect liver functional 
capacity. Although the LiMax test has been shown to be an independent predictor of 
postoperative mortality and morbidity, there is still limited experience with this 
method106.  
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1.5.4 Imaging-based liver function analysis 
Cross-sectional imaging modalities such as computed tomography (CT) and magnetic 
resonance imaging (MRI) are invaluable tools for assessing liver anatomy and 
resectability of primary or secondary liver tumours, giving information on their size, 
location and number. They are also used for assessing tumour response to oncologic 
treatment. Furthermore, they can provide information on the status of the liver 
parenchyma, suggesting steatosis or liver cirrhosis, but give no quantitative information 
about liver functional capacity107. By using imaging modalities in combination with a 
hepatocyte-specific tracer, non-invasive sampling of the tracer is possible from all 
compartments visible with the imaging modality used. This usually involves sampling 
of blood and liver parenchymal tracer concentrations, from which quantitative 
functional parameters are calculated. Depending on the temporal and spatial resolution 
of the imaging modality, even sampling from the biliary compartment, bowel and the 
renal system can be performed. 
 
1.5.4.1 Volumetric assessment 
Cross-sectional imaging can be used to assess total liver volume and predict remnant 
liver volume (RLV) after resection with good reproducibility and low inter-observer 
variation, and has gained widespread use in hepatobiliary surgery108, 109. There is no 
general consensus or evidence-based limit for what the safe amount for future RLV is, 
but as could be expected, the risk of postoperative liver failure seems to increase with 
decrease in liver remnant size. In a worldwide survey of 133 centres performing liver 
surgery, a median value of 25% (range 15-40%) in healthy livers was regarded as a safe 
limit for RLV, and 50% (range 25-90%) as the limit in chronic liver disease103. Studies 
assessing the efficacy of liver volumetry to predict postoperative morbidity and 
mortality are contradictory and many different ways are used to report the future liver 
remnant, making comparison difficult. In a study on 126 patients undergoing surgery 
for colorectal liver metastases, Shoup et al found that patients with RLV <25% were at 
higher risk for postoperative hepatic dysfunction and other postoperative complications, 
compared to the patients with RLV >25%110. Still a significant number of patients with 
RLV >25% developed hepatic dysfunction, as did a few with >40% RLV. Ferrero et al 
found that liver resection could be safely performed when the future RLV was >26.5% 
in healthy livers, and >31% when liver function was impaired111. Shirabe et al related 
the RLV to the body surface area and found in a study on 80 patients with hepatitis 
undergoing resection for HCC that RLV of <250 ml/m2 was associated with an 
increased risk of liver failure (38%)112. Another approach was used by Chun et al in a 
study on 68 non-cirrhotic patients who underwent liver resection after portal vein 
embolization113. In this study, the RLV was estimated from CT images, and the 
predicted RLV was related to the estimated total liver volume predicted by body 
surface area, and to body weight114. The study showed that safe hepatic resection in 
non-cirrhotic livers could be performed if the RLV to estimated total liver volume ratio 
was >20% or future RLV to body weight ratio was >0.4. In an attempt to predict the 
actual functional capacity of the remnant liver, Stockmann et al combined the LiMax 
test with volumetric assessment from CT images for a combined volume and function 
analysis to predict residual LiMax capacity after resection106. In a retrospective analysis 
he found that postoperative LiMax values less than 80µg/kg/h were associated with a 
38% risk of mortality. It was also found that mortality was significantly decreased 
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when prospectively using volumetry and LiMax combined, avoiding resection in 
patients where the predicted remnant liver function assessed was below this critical 
value. 
 
1.5.4.2 Scintigraphic assessment of liver function 
Hepatobiliary scintigraphy (HBS) utilizes a hepatocyte-specific radioactive tracer often 
labelled with 99Technetium (99Tm). Most commonly the tracer is derived from the 
family of iminodiacetic acid (IDA) compounds with 99mTc-mebrofenin being one of the 
most widely studied compounds. Mebrofenin is rapidly and almost exclusively (98%) 
eliminated through the hepatobiliary pathway115. Similar to ICG it is taken up into the 
hepatocyte by the OATP system, specifically OATP1B1 and OATP1B3, the latter a 
transporter shared with ICG94. It is therefore not surprising that ICG clearance has been 
found to closely correlate with the uptake of 99mTc-mebrofenin116. It is rapidly excreted 
into the bile in unchanged form without biotransformation. Since the tracer is 
radioactive, the decay can be registered outside the body with a γ-camera, either using 
planar scintigraphy or single photon emission computed tomography (SPECT). Planar 
scintigraphy provides a 2-dimensional image of the object examined, and is especially 
hampered by low resolution and the artefacts imposed due to differences in thickness of 
different parts of the liver and the inevitable inclusion of non-hepatic tissues in the 
planar projections. SPECT has better resolution and the ability to produce true 3D 
representations and cross-sectional images with a defined slice thickness, allowing 
identification of anatomical structures, as well as assessment of regional liver function. 
HBS using IDA compounds has been used in several studies to investigate liver 
function in the context of hepatology, liver surgery and liver transplantation116-124.  
 
Liver function can also be assessed using Technetium-99m-galactosyl human serum 
albumin (99mTc-GSA). GSA is a glycoprotein with affinity for the liver specific 
asialoglycoprotein receptor (ASGP). After binding to the receptor, it is internalized into 
the hepatocyte by means of endocytosis. A decrease in ASGP receptors is seen in 
chronic liver disease, and results from 99mTc-GSA have been shown to closely correlate 
to other liver function tests, liver histology and scoring models125, 126. After intravenous 
administration of 99mTc-GSA, the liver and heart activity are registered, either using a 
conventional planar γ-camera or SPECT. At least 14 different parameters that describe 
various aspects of 99mTc-GSA hepatic kinetics have been described in the literature, 
making comparison of studies difficult127. The use of 99mTc-GSA scintigraphy has been 
evaluated in several studies for preoperative assessment of liver function, for example 
by Kwon et al who found a correlation between 99mTc-GSA and ICG clearance, but the 
ability of 99mTc-GSA to predict postoperative morbidity and mortality was better than 
for ICG clearance128. 99mTc-GSA has also been used to assess liver hypertrophy after 
portal vein embolisation, with the interesting findings that function seems to increase 
faster than volume, which has also been noted in studies on postoperative liver 
regeneration127, 129-131. A drawback with GSA scintigraphy is that, at present, it is 
commercially available only in Japan. 
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1.6 MAGNETIC RESONANCE IMAGING (MRI) 
1.6.1 Basic principles of nuclear magnetic resonance 
Magnetic resonance imaging is based on the physical properties of the hydrogen atom 
(1H), with a nucleus that consists of a single proton that carries a positive charge and a 
fundamental characteristic known as spin. Due to the spin and the positive charge, the 
proton has a magnetic dipole 
moment, and in a classical image 
the hydrogen proton can be seen 
as a spinning magnetic dipole with 
a magnetic vector. When the weak 
magnetic field created by the 
spinning proton is placed in an 
external magnetic field (B0) the 
proton will align its spin either 
parallel or anti-parallel to the 
external field. Slightly more spins 
will align in the parallel direction, 
since this is the lower energy state. 
The magnetic field of each proton wobbles around the field lines of the external field. 
The wobbling motion resembles a spinning gyroscope and the spinning motion is called 
precession and is exemplified in Figure 5. The precession speed, also called the Larmor 
frequency, is proportional to the strength of the external field and is given by the 
Larmor equation, 
 
          [Eq 1] 
 
where ω0 is the Larmor frequency, γ0 is the gyromagnetic ratio (γ=42.58 /MHz/T for 
the hydrogen nucleus) and B0 is the magnetic field strength in Tesla (T). The individual 
magnetic vectors of the spinning protons will add to a net magnetization vector M0 that 
builds up as the system reaches a steady-state. If energy is added to the system through 
an electromagnetic pulse with the same frequency as the Larmor frequency (the 
resonance frequency, hence magnetic resonance), a number of protons become excited 
by the added energy and align anti-parallel to the external field, thus shifting the 
direction of the net magnetization vector M0. The electromagnetic energy is induced by 
a radio transmitter through a radiofrequency (RF) pulse by an external antenna coil, 
which transmits energy to the hydrogen nuclei, and also causes them to precess in-
phase. As more energy is added to the system the magnetization vector will tip further 
and become more and more perpendicular to the field-lines of the external magnetic 
field. This way the magnetization vector is split into a longitudinal part Mz, known as 
the longitudinal magnetization, and a transversal part Mxy, known as the transversal 
magnetization. The direction of the magnetization vector depends on the total energy 
deposited, if the RF pulse is long and strong enough it will cause the magnetization 
vector to tip away 90° from the z-axis and the magnetization vector thus only has a 
transversal component. Such an RF-pulse is known as a 90° pulse, and it is this latter 
phenomenon that creates the transverse magnetization. The system has now reached a 
state called excitation. The excitation state of the hydrogen protons is unstable and as 
soon as the transmission of the RF-pulse ends, the longitudinal magnetization vector 
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will start to regain its strength whilst the transverse magnetization fades, a phenomenon 
known as the relaxation of the system. The relaxation consists of two independent but 
simultaneous processes that lead to the return to the stable system that was present 
before the excitation. One of these is the longitudinal relaxation, which is caused by the 
protons precessing anti-parallel to the external magnetic field returning to a parallel 
spin, since this is the lower energy state. This causes the longitudinal magnetization 
(Mz) vector to gradually regain its strength. The longitudinal relaxation is also known 
as the T1-relaxation. The time it 
takes for the Mz vector to return 
to 63% of its original strength is 
known as the longitudinal 
relaxation time or T1. As the 
external RF pulse is switched off, 
the protons that were forced to 
precess in-phase will gradually 
lose their phase coherence and 
thus the transverse net 
magnetization vector will fade 
away gradually. This is called the 
T2-relaxtion and the time it takes 
for the transverse magnetization vector to fade to 37% of the original (maximum) value 
is the time-constant called T2. Generally T1 is longer than T2 and generally T1 and T2 
are longer in liquids than in fat. The transverse magnetization, created by a by a 
radiofrequency pulse, in turn creates a radio signal when it decays, and this signal can 
be detected with an external antenna. The radio signal decays as the transverse 
magnetization vector fades, and the time this takes is dependent on the T1 and T2 of the 
tissue placed in the magnetic field. 
 
1.6.2 Magnetic resonance imaging 
The principles of nuclear magnetic resonance described above have been used to create 
images of a body or other objects placed in the magnetic field, as suggested by the 
Nobel laureates Mansfield and Lauterbur. The process is known as magnetic resonance 
imaging (MRI). An MRI scanner consists of a large permanent or superconducting 
magnet that creates a strong magnetic field, typically 1.5 or 3 Tesla (T) for 
superconductive systems. As a comparison, the field strength of the earth’s magnetic 
field varies between 30 and 60 µT. In addition to the large magnet there are typically 
three magnetic coils that produce magnetic field gradient in the x, y and z directions, 
i.e. 3-dimensional (3D) magnetic field strength gradients can be applied. The additional 
magnetic coils are referred to as gradient coils. By switching on a gradient in the z 
direction, protons along this axis of the magnetic field will precess with unique Larmor 
frequencies, a phenomenon referred to as gradient encoding. This will allow spatial 
information to be coded into and later obtained in the z direction, equivalent to 
obtaining an image slice, since the RF pulse of a defined frequency will only excite 
those hydrogen atoms that precess with that same frequency. How ―steep‖ this gradient 
is will determine the slice thickness, with thinner slices obtained in a steeper gradient. 
By switching on a magnetic field gradient perpendicular to the z direction, i.e. the x or 
y directions in the previously selected slice, the already excited protons will start to 
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precess with slightly different frequencies and with different phases, referred to as 
frequency encoding. This is repeated in the same direction with a slightly different 
phase each time, referred to as phase encoding. As a consequence, the RF signals 
emitted from the system as it relaxes will have slightly different frequencies and phases 
depending on where the signals originated from. The antenna that produces the RF 
pulse for the excitation of the protons is usually integrated into the scanner, whereas the 
receiving antennas or RF coils are usually smaller and designed for the particular part 
of the body to be examined, e.g. the brain, knee or abdomen. After the weak radio 
signal emitted from the examined object is detected by the receiving RF coils, the radio 
signals are converted into images using complex mathematical calculations including 
Fourier transforms. 
 
1.6.3 Pulse sequences 
By repetition of the transmitted RF pulse in combination with changes in the external 
field gradient strength and direction, the inherent T1 and T2 of a tissue or fluid can be 
used for tissue characterization in a vast variety of ways. Ultimately, this is what will 
cause the tissue-tissue contrast in the images obtained in MRI. The order in which the 
RF pulses are emitted and received and the timing when the magnetic field is turned on 
and off is referred to as a pulse sequence. There are several parameters that can be 
altered in a pulse sequence. The time between two excitation RF pulses is referred to as 
the repetition time (TR) and the time between the excitation RF pulse and the 
registration of the emitted RF signal is referred to as the echo time (TE). As described 
above, an RF pulse of sufficient length will tip the magnetization vector 90°. A shorter 
RF pulse will tip the angle less and this angle is referred to as the flip angle. A typical 
T1-weighted pulse sequence has a short TR and short TE, and in addition, usually a low 
flip-angle. When a pulse sequence is designed it will inevitably be a compromise 
between spatial resolution, total anatomical coverage, signal-to-noise ratio (SNR), 
acquisition time, artefacts and contrast resolution132. 
 
Images where the contrast is mainly derived from T1 relaxation are known as T1-
weighted and accordingly, images that rely on T2 relaxation are referred to as T2-
weighted. In a T1-weighted image, water will appear dark and fat lighter, with the 
reverse in T2-weighted images. In imaging using repetitive image acquisition, e.g. 
dynamic imaging, there is often a need for short image acquisition times with preserved 
spatial and contrast resolution, as well as sufficient SNR. The most frequently used 
pulse sequences for dynamic T1-weighted imaging are known as gradient echo 
sequences, allowing for fast image acquisition with sufficient spatial resolution. When 
MRC is performed, either T2-weighted imaging with long echo times can be applied to 
generate images of the bile ducts, since the bile is relatively rich in water, which has a 
long T2. This technique does not require any tracer to be injected. An alternative 
technique to perform MRC is to obtain T1-weighted images after injection of a 
hepatocyte-specific contrast agent and to obtain the images in the biliary excretion 
phase. 
 
1.6.4 Signal intensity and image analysis in MRI 
Signal intensity and SNR in MRI depend on inherent tissue properties, magnetic field 
strength and field inhomogeneity, the pulse sequence used and the hardware of the 
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scanner, especially the receiving RF coils. The SNR is also dependent on the slice 
thickness, matrix size and field of view (FOV). Signal intensity can also be influenced 
by the introduction of a contrast agent into the system. 
 
When the RF signal is received in the receiving RF coils, it is converted into an image 
made up of elements called pixels (picture elements). Each pixel is a representation of a 
particular position in the 3D x, y and z space defined by the pulse sequence and 
predefined imaging parameters. The smaller the pixel, the better resolution the final 
image will have, but SNR will be lower. The RF signal intensity for a specific pixel is 
represented on a greyscale going from black to white, and all pixels together form the 
greyscale image seen in MRI. The pixel is a two-dimensional representation of a 3D 
volume and is therefore sometimes referred to as a voxel (volume element). When 
tracer dynamics are to be investigated, repetitive sampling is required and the images 
obtained will represent a dynamic process over time. This can be described by a graph 
where the y-axis represents, for example, signal intensity or relative signal intensity 
compared to native images and the x-axis is the time-line. The resulting graph will be a 
signal intensity-over-time curve (SI/time-curve) or the relative enhancement/relative 
signal intensity-over-time (RE/time-curve or SIr/time-curve), depending on the post-
processing. Such curves can either be derived from individual voxels or a group of 
voxels in a defined area, often referred to as a region-of-interest (ROI). When analyzing 
these curves, the relationship between contrast agent concentration and the resulting 
changes in signal intensity also has to be taken into account. Generally, signal intensity 
changes are proportional to changes in contrast agent concentration. 
 
1.6.5 MRI-derived tissue functional parameters 
To evaluate tracer dynamics, different strategies can be applied. For example, a simple 
way to evaluate liver parenchymal enhancement would be to let an observer judge the 
enhancement in an image as absent, small, moderate or significant. Another way could 
be a visual inspection and grading of the SI/time-curves obtained from repetitive 
sampling in dynamic MRI. In many cases such strategies might be sufficient, but the 
reproducibility could be questioned. In order to increase reproducibility, more advanced 
measures to quantify and describe tracer dynamics have been applied by deriving 
descriptive parameters from the SI/time-curves. 
 
1.6.5.1 Semi-quantitative parameters 
Parameters can be defined as 
semi-quantitative when the 
impact of the input function (i.e. 
the amount of tracer in the 
circulating blood-pool) on the 
resulting SI/time-curve is not 
accounted for. Basically these 
parameters are designed to give a 
description of the parenchymal 
response function and include 
maximum signal intensity (Smax) 
or maximum concentration 
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(Cmax), time to maximum signal intensity (tmax), signal intensity half-time (t1/2), and area 
under the SI/time-curve (AUC), as shown in Figure 7. The semi-quantitative 
parameters have their advantages in that they are easily accessible, intuitive and require 
limited post-processing. A semi-quantitative representation of tracer dynamics can also 
be acquired by dividing the enhancement of one organ by the other, e.g. the liver to 
muscle or liver to spleen enhancement ratio. 
 
1.6.5.2 Quantitative parameters and compartmental pharmacokinetic modelling 
The flow of a contrast agent between compartments such as the plasma compartment 
and extracellular space can be assessed using compartmental modelling, typically using 
extracellular contrast agents. This method is often referred to as dynamic contrast-
enhanced MRI or DCE-MRI, and typically studies the permeability of the vascular 
bed133. Originally DCE-MRI was utilized in studies of the brain, but it has also been 
applied in MRI of the liver and other organs to study the vascular permeability in 
tumours and effects of anti-angiogenic chemotherapy134. Compartmental modelling has 
also been used to study the liver uptake and excretion of the hepatocyte-specific 
contrast agent Gd-BOPTA in rats135-137.  
 
1.6.5.3 Quantitative parameters and deconvolutional analysis 
The amount and rate of tracer extraction from the vascular compartment by an organ is 
dependent not only on organ-specific characteristics, but also on the amount of tracer 
presented to the organ over time, i.e. the input function. The organ-specific 
characteristics regarding tracer kinetics, in this case the liver, can be represented by the 
impulse response function. If the input function is ideal, i.e. an infinitely short 
intravascular bolus directly into the liver without recirculation, the response function 
y(t) will equal the impulse response h(t), as shown in Figure 8 (I). In vivo the input 
function consists of the 
intravenously injected tracer 
which will be dispersed over 
time. The amount of dispersion 
is dependent on several factors, 
such as injection speed, site of 
injection, distribution volume 
of the tracer, cardiac output 
and other routes of elimination 
of the tracer used. The liver 
will therefore constantly be 
presented with changing 
concentrations of tracer. The in 
vivo input function is therefore 
not ideal and will greatly affect the response function y(t) as shown in Figure 8 (II). 
Mathematically the response function of an organ can be described as a convolution 
between the impulse response and the input function, 
 
   txthty )(    [Eq 2] 
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where y(t) is the response function, h(t) the impulse response and x(t) the input 
function. The response function y(t) and the input function x(t) can be measured, but 
h(t) will remain unknown. However, with knowledge of the input and response 
functions the impulse response can be estimated by deconvolutional analysis (DA).  
 
From the impulse response curve, several functional characteristics of the system can 
be derived, such as extraction fraction (EF), peak blood flow relative to the input 
function (input relative blood flow, irBF), area under the curve (AUC) and mean transit 
time (MTT), which is equal to AUC/irBF. The use of DA has previously been 
described in DCE-MRI of the kidneys 138, 139, and also in several studies using 
scintigraphy to investigate liver function117, 121, 140-149. The parameters obtained are 
sometimes referred to as model-free parameters since their calculation does not require 
any model-based assumptions, such as in compartmental modelling. 
 
In the previously mentioned 
liver function studies, the EF 
was referred to as the hepatic 
extraction fraction (HEF) 117, 
121, 141-144, 150. Figure 9 shows a 
typical impulse response curve 
derived from liver parenchyma 
after DA using Gd-EOB-
DTPA as tracer. The hepatic 
extraction (HE) curve can be 
divided into the initial vascular 
phase and the later hepatocyte 
retention, or parenchymal 
phase, as is also demonstrated in Figure 9. In the scintigraphic studies the calculation of 
HEF was performed by fitting a mono-exponential curve to the HE-curve in the 
parenchymal phase. The mono-exponential fitted curve, the hepatic retention curve 
(HRC), is extrapolated back to the time of the vascular peak value (i.e. t=0), and HEF is 
defined as the ratio between the intersection of the extrapolated HRC curve on the y-
axis and the vascular peak of the HE curve, as illustrated in Figure 9 and described by 
Equation 3, 
 
)(
)(
0max
0
tHE
tHRCHEF     [Eq 3] 
 
MTT is the area under the impulse response curve (AUC) from peak value to 0 divided 
by the peak value of the curve (equal to irBF), and describes the mean time for a unit of 
the studied substance from entrance into the ROI to exit, which in the case of the liver 
can be either by excretion into the bile ducts or vascular wash-out. 
 
DA can be performed using several mathematical methods, including Fourier analysis 
(FA) or matrix inversion. FA is described as shown in Equation 4: 
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where FT is the Fourier transform and FT-1 the inverse Fourier transform. FA has the 
advantage of being straightforward, but suffers from high-frequency artefacts resulting 
from the abrupt end points of x(t) and y(t). To avoid this abrupt end of data, a smooth 
appended curve can be added to the end of x(t) and y(t) to bring these curves down to 
zero. This is generally done by appending a cosine function from 0 to π/2 with the 
initial height of the last point of x(t) and y(t)145. 
 
By formulating the convolution in Equation 1 into matrix form, the equation can 
instead be solved by matrix inversion, using singular value decomposition (SVD) as 
shown below: 
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Since A is a square matrix it will divide into SVD as, 
 
   [Eq 6] 
 
where U and V are orthogonal (i.e. their inverses equal their transposes) and W is 
diagonal with the elements wi such that 
 
0...21  Nwww    [Eq 7] 
 
h(t) is solved through matrix inversion: 
 
  [Eq 8] 
 
If one or more of the wi are zero or close to zero, the matrix inversion becomes ill-
conditioned. Hence, noise in the data becomes magnified in the least square solution 
(i.e. Equation 8), and makes the result of no practical value. One solution to this 
problem is the principle of regularization, or more specifically, truncated SVD (TSVD). 
In TSVD the threshold c was defined as N(1-c), where N is the total number of singular 
values and c the threshold, ranging from 0 to 1. For singular values beyond this cut-off, 
1/wi is not computed, but instead replaced by zero. 
 
1.6.6 Gd-EOB-DTPA (gadoxetic acid) 
The first contrast agent for MRI to be approved for clinical use was Gd-DTPA 
(Magnevist®, Bayer Schering Pharma, Berlin, Germany), which was introduced in 
1988. It was followed by a number of other substances and in 2004 Gd-EOB-DTPA 
(gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid, gadoxetic acid, 
gadoxetate (Primovist®, Bayer Schering Pharma, Berlin, Germany)), was introduced 
on the market in Europe. Like other gadolinium-based contrast agents, Gd-EOB-DTPA 
utilizes the paramagnetic properties of the gadolinium (Gd) atom and the dipole-dipole 
  Ti
T VwdiagUVWUA  )(
  )()/1(1 yUwdiagVhyAh Ti 

 24 
interactions it exerts on the hydrogen atoms. Due to these interactions, the presence of 
Gd in a tissue will induce a shortening of the T1 relaxation. The gadolinium atom is a 
toxic heavy metal atom and therefore needs to be chelated to other substances to reduce 
its toxicity. Depending on the pharmacological properties of the Gd ligand, the 
tumbling rate will differ. The closer this tumbling rate is to the Larmor frequency, the 
more T1 relaxtion will occur. The capacity of a Gd compound to induce T1 relaxation 
is referred to as the longitudinal relaxivity (r1) of the contrast agent and is measured in 
(s-1mM-1). The relaxivity is dependent not only on the magnetic field strength and 
temperature, but also on the amount of plasma protein binding of the substance151. 
Therefore, a contrast agent does not necessarily have the same relaxivity in blood, 
plasma or tissue as it has in water or a saline solution152, 153. Animal studies have shown 
that the relaxivity of Gd-EOB-DTPA in liver (r1=9.3 s-1mM-1) differs somewhat from 
that in blood (r1=7.3 s-1mM-1) at 1.5 T154. 
 
To distinguish dynamic MRI with a hepatocyte-specific agent used as tracer from 
conventional DCE-MRI with extracellular agents, the former will in this work be 
referred to as dynamic hepatocyte-specific contrast-enhanced MRI or DHCE-MRI. 
 
1.6.6.1 Pharmacologic properties of Gd-EOB-DTPA 
Gd-DTPA is a highly hydrophilic compound and therefore distributed strictly in the 
extracellular compartment, and eliminated almost exclusively through the kidneys155. 
Gd-EOB-DTPA on the other hand is slightly more lipophilic due to the addition of the 
ethoxybenzyl group. After intravenous injection it is distributed in the extracellular 
space with a relatively low plasma protein binding (10%), and a distribution volume of 
approximately 0.21 L/kg155, 156. It is generally well tolerated with few serious side 
effects156, 157. From the blood stream, Gd-EOB-DTPA is actively taken up into 
hepatocytes mainly through a carrier-mediated system, but possibly also by passive 
diffusion. Several studies have suggested the organic anion transporting polypeptides 
(OATP) and the Na+/taurocholate cotransporting polypeptide (NTCP) as responsible 
for the transmembranous transport of Gd-EOB-DTPA 158-161. It has also been shown 
that the uptake of Gd-EOB-DTPA and subsequent enhancement of hepatocellular 
carcinoma cells is highly dependent on the expression of the OATP8/1B3 isoenzyme162-
164.This uptake mechanism is shared in part with ICG and mebrofenin used for liver 
function assessment as previously mentioned. From the hepatocyte, Gd-EOB-DTPA is 
excreted in an unchanged form into the bile canaliculi by the ATP dependent multidrug 
resistance protein (MRP2), also known as ABCC2165, 166. The MRP2 enzyme is also 
involved in the excretion of bilirubin from the hepatocyte. Gd-EOB-DTPA in plasma is 
also eliminated by glomerular filtration in the kidneys in about equal amounts as by the 
hepatobiliary pathway (43.1-53.2% and 41.6-51.2% respectively), and the plasma half-
life is approximately one hour156. As could be expected when liver function is impaired, 
biliary excretion is decreased and subsequently the proportion eliminated by renal 
excretion is increased167. 
 
1.6.6.2 Clinical use 
Gd-EOB-DTPA is commercially available in large parts of the world as Primovist® 
(Europe and Asia) or Eovist® (USA). Gd-EOB-DTPA is provided in a solution of 0.25 
mmol/mL, with the normal clinical dose being 0.1mL/kg. In the first phase after 
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intravenous administration, the major part of the administered dose of Gd-EOB-DTPA 
is still in the blood stream and can therefore be utilized in the same fashion as 
extracellular contrast agents, for example for vascular imaging159. In later phases, due 
to the hepatocellular uptake of the contrast agent and subsequent shortening of T1 
relaxation, hepatocytes will enhance more on T1-weighted imaging compared to tissue 
and liver lesions that do not contain hepatocytes. In healthy liver tissue, there is a 
maximum enhancement about 20 minutes after the intravenous administration156. In 
several studies the hepatocyte-specific properties of the substance have been shown to 
increase both the detection rate of liver lesions and the ability to characterize these 
lesions168-173. In later phases there is biliary excretion and Gd-EOB-DTPA can be used 
for T1-weighted MRC, as well as for the detection of bile leaks and bilomas174-176. 
 
1.6.6.3 Results from animal and human studies on liver function 
A early as 1993 it was suggested that the hepatocyte-specific properties of Gd-EOB-
DTPA could be used to evaluate liver function155. This was followed by several animal 
studies using experimentally induced hepatocellular damage. Schmitz et al found that 
elimination half-lives of Gd-EOB-DTPA using both scintigraphy (153Gd-EOB-DTPA) 
and MRI were significantly prolonged in rats with common bile duct obstruction or 
chemically induced fatty liver177. Kim et al induced hepatocellular injury in rats using 
intraperitoneal administration of carbon tetrachloride (CCl4) solution, and found a dose-
dependent decrease in maximum liver relative enhancement and relative enhancement 
half-time. These findings were also significantly correlated to ICG half-time and serum 
levels of bilirubin and prothrombin time178. In a study on regional liver function 
utilizing a rat ischemia-reperfusion model, Shimizu et al found that when selectively 
clamping the right liver lobe for 30, 60 and 90 minutes in three groups of rats, there was 
a significant increase in relative enhancement in late-phase T1-weighted images from 
the ischemic lobe compared to the non-ischemic liver lobe in the 60 and 90 minutes 
ischemia rats. Furthermore, a significant correlation between relative enhancement 
half-time and clamping time was observed. They also analyzed the ATP concentration 
in the harvested rat livers and found a significant correlation between ATP content and 
relative enhancement half-time, suggesting that this may reflect the function of the ATP 
dependent biliary excretion of Gd-EOB-DTPA and hence the energy status of the 
liver179. Using DA to calculate HEF, Ryeom et al showed that after inducing liver 
injury to rabbits by repetitive administration of CCl4, the ICG-R15 increased as HEF 
decreased with an almost linear relationship180. In two studies from Tsuda et al, the 
ability of Gd-EOB-DTPA enhanced MRI to differentiate between liver steatosis and 
NASH and the progression of fibrosis in NASH were demonstrated. The first study 
showed significantly later tmax and relative enhancement t1/2 in the NASH group 
compared to the steatosis group181. The second study found significant correlations 
between tmax, t1/2 and liver fibrosis182. 
 
The first published study that addressed Gd-EOB-DTPA-enhanced MRI and liver 
function in humans was published in 2008 by Tschirch et al183. This study evaluated the 
visualization of the bile ducts in T1-weighted MRC in patients with liver cirrhosis 
compared to normal controls. In the control group, the MRC was judged as sufficient 
after 20 minutes in all subjects, but only in 40% of the cirrhosis group. The study also 
showed that elevated PK-INR and serum bilirubin correlated to insufficient biliary tree 
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visualization183. In a study on 198 patients with chronic liver disease and cirrhosis, 
Motosugi et al found that the liver-to-spleen contrast ratio at 10 and 20 minutes 
correlated to ICG R15 and Child-Pugh class, but not to serum albumin, bilirubin or 
prothrombin time184. Like Tschirch et al, Takao et al also addressed the visualization of 
bile ducts in patients with chronic liver disease compared to healthy controls. Although 
the patients in this study had less pronounced liver dysfunction it was found that the 
signal intensity in the major bile ducts at tmax was significantly lower in the patient 
group and that ICG R15 was a significant predictor of the signal intensity of the major 
bile ducts185. The effects of liver function on parenchymal enhancement after 
administration of Gd-EOB-DTPA was investigated by Tajima et al in a study where 
signal-to-noise ratio was measured in a group of 48 patients with either impaired or 
normal liver function186. They found significantly lower signal intensity in the 
parenchyma of patients with chronic liver disease compared to the group with normal 
liver function. A significant correlation between parenchymal signal intensity and ICG 
R15 was also noted186. A more advanced way to quantify the hepatic uptake of Gd-
EOB-DTPA was applied by Katsube et al in a study where actual T1 relaxation time 
and not signal intensity in the liver parenchyma was measured before and at different 
time-points after administration of Gd-EOB-DTPA. The study involved a total of 91 
patients who either had normal liver function, chronic hepatitis or liver cirrhosis graded 
as Child A or B. The reduction in T1 relaxation time was significantly affected by liver 
function, mirroring the decreased uptake of Gd-EOB-DTPA in liver disease187. 
Significant correlations between parameters obtained by 99mTc-GSA scintigraphy and 
those obtained from dynamic Gd-EOB-DTPA enhanced MRI were found in a study on 
33 patients by Nishie et al188. 
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2 AIMS 
2.1.1 Paper I 
The aim of the first study was to assess the feasibility of calculating HEF and irBF on a 
segmental level using DHCE-MRI, and to evaluate two different mathematical 
strategies for DA: FA and TSVD. 
 
2.1.2 Paper II 
The aim of the second study was to compare the results of DHCE-MRI-derived 
quantitative and semi-quantitative parameters in PBC patients with normal controls. 
For the patient group, the aim was also to explore the correlation between DHCE-MRI 
derived parameters and the CPS, MELD and Mayo risk score. 
 
2.1.3 Paper III 
The aim of study three was to use DHCE-MRI for global and segmental liver volume 
assessment and also to quantitatively evaluate global and segmental liver function. A 
secondary aim was to explore the heterogeneously distributed liver function in PSC by 
comparing the discrepancies in function and volume in PSC patients with those in a 
healthy control group. In the patient group, an aim was also to assess the correlations of 
global functional parameters with the CPS, MELD and Mayo risk scores and to assess 
the correlations of cholangiographically graded bile duct obstruction with segmental 
functional parameters. 
 
2.1.4 Paper IV 
The primary aim of Paper IV was to investigate patients with liver cirrhosis with 
DHCE-MRI to detect possible discrepancies in the segmental distribution of liver 
volume and function and by using a simulation of surgical decision-making, to 
demonstrate the effect of non-homogeneous dysfunction on predicted residual liver 
function. A secondary aim was to explore the correlation of DHCE-MRI-derived liver 
function parameters with the CPS and MELD-score, and to assess the ability of the 
studied parameters to discriminate between groups with normal and compromised liver 
function. 
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3 MATERIAL AND METHODS 
3.1 STUDY SUBJECTS 
All studies were approved by the Regional Ethical Review Board in Stockholm and 
informed consent was obtained from all participants prior to examination. All study 
participants were asked to be fasting for at least four hours prior to the MRI 
examination. 
 
3.1.1 Paper I 
The study was performed on 20 healthy volunteers, 10 men and 10 women, age ranging 
from 22 to 45 years without history of hepatobiliary disease, previous hepatobiliary 
surgery or alcohol abuse. No abnormal serum liver function tests or signs of renal 
insufficiency were found among the participating study subjects. The clinical 
characteristics of the control group are presented in Table 4. 
 
 
Table 4: Characteristics of healthy volunteers (control group) 
 Controls (n=20) (Reference) 
Gender (m/f) 10/10   
Age (years) 33.2 ±6.8 (20)   
    
Bilirubin (µmol/L) 12.6 ±5 (9)  <26 
Albumin (g/L) 42 ±2 (19)  36-48 
Creatinine (µmol/L) 83 ±17 (19)  <100(men); <90(women) 
PK-INR (INR) 1.1 ±0.1 (19)  <1.2 
ALP (µkat/L) 1.04 ±0.46 (19)  <1.9 
ALT (µkat/L) 0.41 ±0.26 (20)  <1.20(men); <0.76(women) 
AST (µkat/L) 0.32 ±0.08 (20)  <0.76(men); <0.61(women) 
Values represent means ± standard deviation (SD) 
(Numbers within brackets in the middle column denote number of observations)  
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3.1.2 Paper II 
Twelve patients with PBC were included in the study and the 20 healthy volunteers 
from the first study were used as controls. For patients, relevant demographic and 
clinical data were documented, as well as the results of LFTs from the most recent visit 
documented in their clinical charts. The CPS, MELD and Mayo risk score were 
calculated for each patient. The patient characteristics are presented in Table 5. Patients 
in the PBC group were older than the controls and gender-wise an expected female 
predominance was observed. Liver disease in the patient group as a whole was mild, as 
can be seen in the relatively low CPS, MELD and Mayo risk scores. 
 
 Table 5: PBC patient characteristics 
 Patients (n=12) (Reference) 
Gender (m/f) 1/11   Age (years) 62.8 ±7.5   
    Bilirubin (µmol/L) 14 ±9  <26 
Albumin (g/L) 36 ±4  36-48 
Creatinine (µmol/L) 67 ±10  <100(men); <90(women) 
PK-INR (INR) 1.0 ±0.2  <1.2 
ALP (µkat/L) 3.52 ±3.85  <1.9 
ALT (µkat/L) 0.74 ±0.41  <1.20(men); <0.76(women) 
AST (µkat/L) 0.77 ±0.48  <0.76(men); <0.61(women) 
Values represent means ±SD 
Disease characteristics of PBC patients 
  
Median / 
proportion (Min – Max) 
MELD 6   6 - 14 
CPS 5.5 5 - 7 
Mayo risk score 5.4 4.0 - 7.8 
   Ursodeoxycholic acid treatment (yes/no) 11/1  
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3.1.3 Paper III 
Twelve patients with PSC were included and the 20 healthy volunteers from the first 
study were again used as controls. For patients, relevant demographic and clinical data 
were documented, as well as results of serum LFTs from the visit closest to the MRI 
examination date documented in their clinical charts. The CPS, Mayo risk score and 
MELD-score were calculated for each patient. The PSC patient characteristics are 
presented in Table 6. 
 
 
Table 6: PSC patient characteristics 
 Patients (n=12) (Reference) 
Gender (m/f) 6/6   
Age (years) 43.8 ±15.8   
    
Bilirubin (µmol/L) 11 ±6  <26 
Albumin (g/L) 37 ±5  36-48 
Creatinine (µmol/L) 67 ±16  <100(men); <90(women) 
PK-INR (INR) 1.1 ±0.2  <1.2 
ALP (µkat/L) 3.52 ±3.90  <1.9 
ALT (µkat/L) 1.54 ±1.81  <1.20(men); <0.76(women) 
AST (µkat/L) 1.09 ±1.14  <0.76(men); <0.61(women) 
Values represent means ±SD  
Disease characteristics of PSC patients  
 Median / proportion (Min – Max) 
MELD  6.5    6 - 13 
CPS 5  5 - 7 
Mayo risk score 0.06 -1.65 - 0.85 
   
Ursodeoxycholic acid treatment (yes/no) 8/4  
Ascites (yes/no) 0/12  
History of endoscopic sphincterotomy (yes/no) 1/11  
History of variceal bleed? (yes/no) 0/12  
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3.1.4 Paper IV 
Ten patients with varying degrees of alcohol- and/or viral hepatitis-induced liver 
cirrhosis were included in the study. The patients were regularly seen as outpatients 
participating in a screening program for HCC, or had a history of liver decompensation 
requiring hospitalization. For patients, relevant demographic and clinical data were 
documented, as well as results of serum liver function tests from the visit closest to the 
MRI examination date as documented in their clinical charts. The CPS and MELD-
score were calculated for each patient. Patient characteristics for the cirrhosis patients 
are presented in Table 7. The control group again consisted of the healthy volunteers 
examined in the first study. 
 
 
Table 7: Cirrhosis patients clinical characteristics 
 Patients (n=10) (Reference) 
Gender (m/f) 8/2   
Age (years) 55.8 ±5.3   
    
Bilirubin (µmol/L) 35 ±23  <26 
Albumin (g/L) 32 ±8  36-48 
Creatinine (µmol/L) 91 ±23  <100(men); <90(women) 
PK-INR (INR) 1.4 ±0.3  <1.2 
ALP (µkat/L) 2.28 ±1.04  <1.9 
ALT (µkat/L) 0.97 ±0.69  <1.20(men); <0.76(women) 
AST (µkat/L) 1.47 ±1.13  <0.76(men); <0.61(women) 
Values represent means ±SD 
Disease characteristics  
  Median (Min-Max) 
    
MELD   13 6 -19 
CPS  7 5 - 12 
CPC (n)   
A  4   
B  5   
C  1   
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3.2 MRI PROTOCOL 
In all studies, MRI was performed using a Philips Intera 1.5 T scanner (Best, Holland), 
with a Philips four-channel SENSE body coil. The MRC in Paper III was performed 
using a heavily T2-weighted half-Fourier single-shot fast spin-echo sequence 
(8000/800 ms TR/TE). A 40 mm thick section acquired during breath-hold was 
repeated in 12 different radial projections centred at the common bile duct. The 
dynamic contrast-enhanced sequence was performed using a T1-weighted 3D spoiled 
gradient-echo sequence (TR/TE/flip angle = 4.1 ms/2.0 ms/10°, FOV=415 mm, matrix 
resolution 256x192, 40 slices, slice thickness 10 mm and SENSE factor R=2). The 
volume was imaged in a single breath-hold at repeated time points (12s scan time per 
acquired volume) and the subjects were asked to hold their breath at the same depth 
during each acquisition. Three volumes were acquired pre-contrast for baseline 
calculations in all studies. This was followed by 38 volumes with step-wise increase in 
sampling intervals up to a total sampling time of 90 minutes in Paper I, II and III. In 
Paper IV, the last volume was acquired at 45 minutes after contrast injection, resulting 
in a total of 35 volumes acquired for the patients. For the controls, the images acquired 
after 45 minutes post injection were discarded before analysis in the fourth study. 
Times between sampling volumes were chosen taking into account the subjects’ 
physical capacity, data acquisition requirements and test substance dynamics. A dose of 
0.1 mL/kg Gd-EOB-DTPA 0.25 mmol/mL was injected into the anterior cubital vein, 
coinciding with the start of the fourth acquired volume. The contrast was injected using 
a power injector (Spectris MR injector System, Medrad, Pittsburgh), at an infusion rate 
of 2 mL/s, followed immediately by a bolus of 20 mL of saline (NaCl 0.9%) at the 
same infusion rate. 
 
3.3 IMAGE ANALYSIS AND CALCULATION OF OUTCOME 
PARAMETERS 
In all studies, segments were anatomically defined and the anatomical nomenclature 
adhered to as proposed by Strasberg and the IHPBA14, 15. Segment IV was subdivided 
into IVa and IVb. The horizontal intersegmental plane was defined as being at the level 
of the division of the portal vein into the left and right portal branches. From a seed-
point placed in the IVC, lines were drawn in the plane of the right hepatic vein, middle 
hepatic vein and the falciform ligament/umbilical fissure creating the vertical inter-
sectional boundaries. Segment I was manually outlined in every slice where it was 
visible according to the anatomical landmarks as described by Dodds et al 16. Relative 
signal intensity in the voxels was calculated as the logarithmic ratio expressed in 
Equation 9, 
 
                          [Eq 9] 
SIr(t, ρ) is the relative signal intensity at time t in voxel ρ. S0(ρ) is the mean image 
intensity in voxel ρ from the pre-contrast images, i.e. baseline signal intensity. S(t, ρ) is 
the measured image intensity in voxel ρ at time t. The concentration of tracer in the 
voxel, C(t,ρ), was assumed to be approximately proportional to the relative signal 
intensity in the voxel as described in Equation 10. 
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                  [Eq 10] 
 
For the deconvolution calculations, data points were interpolated to equidistant spacing 
of 60 s over the entire acquisition time length. To minimize effects of noise, mainly due 
to patient motion, low pass filtering of data was used by applying a seven-point sliding 
window filter in both the input and parenchymal response function (SIr/time) curves. 
The impulse response curve resulting from DA was not filtered. For deconvolution 
using FA, an appended tail (FA+tail) was added using a cosine function from 0 to π/2 
with an amplitude of the same height as the last point of x(t) and y(t). The length of the 
tail was set to be three times the length of the total sampling period of 90 minutes. 
When TSVD was used, a static truncation threshold was set at c=0.07. 
 
In all studies, HEF was calculated as described by Equation 3 with the HRC curve 
being a mono-exponential fit to the HE curve from 420 s to 1800 s. The initial time-
point was chosen by visual inspection of the DA-derived impulse response curves, 
where it was clear that the vascular phase of the HE curve had ended and the 
parenchymal phase started. The end time-point was chosen arbitrarily to be 1800 s. The 
perfusion parameter irBF was calculated as the peak value (initial value at t=0) of the 
impulse response curve relative to the peak value of the input function normalized to 1. 
As described above, MTT is the AUC of the impulse response curve divided by the 
peak value of the same curve, which is equal to irBF. Since image acquisition ended 
before the impulse response had reached 0, the HE curve had to be extrapolated down 
to y=0 so that AUC could be calculated. For this purpose, the HE curve was 
extrapolated by a continuation of the mono-exponential fit to t= 3* the time of the 
endpoint (in this work 3*1800 s). At this point, the height of the HE-curve was 
approximately zero. 
 
Image analysis and calculation of functional parameters (both semi-quantitative and 
DA-derived) were performed using the in-house ELEFANT software (Easy LivEr 
Function ANalysis Toolkit) written in MATLAB® (MathWorks, Inc., Novi, MI, USA). 
 
3.3.1 Papers I and II 
In the first two studies, the input function was defined by a ROI placed in the hilar part 
of the portal vein. To ensure that the input function ROI was truly representative of the 
portal vein over the entire acquisition period, it was adjusted manually in each dynamic 
acquisition when needed. Liver parenchymal response function curves were defined by 
placing three parenchymal ROIs in each liver segment, avoiding major blood vessels 
and visible bile ducts. ROI size was chosen arbitrarily by the investigator. For 
calculation of segmental parameters in Paper I, the mean HEF and irBF of the three 
segmental ROIs were regarded as the resulting HEF and irBF for that particular 
segment. In Paper II, the SIr/time-curves of all voxels in the three ROIs combined were 
pooled and regarded as the parenchymal response function of that segment, and HEF 
and irBF were calculated by DA of this response function. In Paper II, global HEF, 
irBF and MTT for each study subject were calculated by obtaining the median of the 
segmental results for the studied parameters. 
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In Paper I, both TSVD and FA were used for DA, whereas in Paper II only TSVD was 
used. 
 
In Paper II, semi-quantitative parameters were also calculated. Maximum relative 
signal intensity (Cmax) and time to maximum relative signal intensity (tmax) were 
calculated directly from the parenchymal SIr/time-curves in the segmental ROIs. Since 
the excretion half-time for Gd-EOB-DTPA is much longer than the time-span used (90 
minutes), t1/2 was calculated using a curve fitting model, given by Equation 11, 
 
                                        [Eq 11] 
 
where f is the fitted curve, and the fitting parameters k2 and TU describe contrast 
uptake, while k1 and t1/2 describe the liver contrast excretion. The starting point for the 
fit was selected to be t = 240s. Apart from segmental calculations of these parameters, a 
global Cmax, tmax and t1/2 was obtained by calculation of the median values of the 
segmental results. 
 
3.3.2 Papers III and IV 
In these two studies, the input function was not derived from the portal vein, but rather 
defined by a ROI placed centrally in the parenchyma of the spleen. To ensure that the 
input function ROI was truly representative of the blood content of the spleen over the 
entire acquisition period, it was adjusted manually when needed. In hepatobiliary phase 
images with optimal contrast between liver parenchyma and surrounding tissues, the 
liver contour was manually outlined in every slice in a caudal-cranial fashion, 
excluding the major hilar vascular and biliary structures. The volumes of all voxels 
within these defining borders were added to obtain total liver volumes for each subject. 
The volume of a liver segment as defined by the liver contour and the inter-sectional 
and inter-segmental boundaries described above, was obtained by adding the volumes 
of all voxels within the segmental borders for that particular segment. Fifty percent of 
the voxels in the intersegmental plane were regarded as representative of the superior 
segments (II, IVa, VII and VIII), and 50% as part of the inferior segments (III, IVb, V 
and VI). The voxel volume, determined by the FOV and matrix resolution parameters 
defined above, was approximately 13 mm3 (1.62x1.62x5 mm). A response function was 
obtained from each individual voxel within the liver contour, with the response 
function being the SIr/time-curve for the voxel. Both TSVD and FA were used for DA 
in these two studies. 
 
Based on findings in Paper I and II, voxels with HEF above 0.7 or irBF above 1 were 
regarded as artefacts and omitted from subsequent analysis regarding functional 
parameters, but were included for calculation of total liver volume. The voxels 
representing vascular structures and not liver parenchyma were expected to have high 
perfusion with high irBF values. Since the study aimed at examining the status of the 
liver parenchyma, the voxels representing vessels were not wanted in further 
calculations. Therefore, upon completion of calculation of irBF for all voxels, those 
with an irBF above a user-defined threshold logically representing vessels, were 
omitted from subsequent analysis, including the liver parenchymal and segmental 
volume calculations. 
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Total liver function was defined as the total hepatocyte extraction capacity of Gd-EOB-
DTPA. This parameter was obtained by adding the individual HEF of all remaining 
(parenchymal) voxels within the liver boundaries and expressed as HEFml. For every 
segment the functional capacity was obtained in a similar fashion, adding all 
parenchymal voxels within the predefined segmental borders. 
 
In Paper IV, a semi-quantitative liver function assessment was also obtained by 
calculating the liver-to-spleen enhancement ratio (LSER) measured at different time-
points. The LSER was calculated by placing three ROIs in each liver segment. The sum 
of all voxels within these three ROIs yielded the parenchymal response curve (SIr/time-
curve) for that particular segment. From these data the SIr in each liver segment at time-
points 10, 20, 30 and 45 minutes post contrast injection was obtained, and divided by 
the SIr of the splenic ROI at the corresponding time-point as shown in Equation 12: 
 
              
                                                      [Eq 12] 
 
Thus four LSER values (LSER-10, LSER-20, LSER-30 and LSER-45) were obtained 
for each segment. A global LSER for the liver at each time-point was obtained by 
calculating the median LSER of all segments for every study subject. 
 
With the aim to explore the heterogeneous distribution of liver function, the differences 
in segmental contributions to total liver function and volume were calculated, and as a 
way to describe the discrepancies between these two variables, absolute and relative 
differences were calculated in every segment. The absolute difference (Adiff %) was 
calculated as described in Equation 13, 
 
                            [Eq 13] 
 
where Snf is the functional capacity expressed as HEFml in segment n, Tf is the total 
liver functional capacity expressed as HEFml, Snv is the volume of segment n and Tv is 
the total liver volume. For every segment, the resulting Adiff% was a negative or positive 
value distributed around 0%. The relative function-to-volume discrepancy (Rdiff) for 
each segment was calculated as expressed in Equation 14 resulting in values distributed 
around 1. 
 
               
 
   
  
      [Eq 14] 
 
For example, if in a patient segment III contributed 14% total liver volume and 18% to 
total liver function, then Adiff %=4 and Rdiff=1.29. 
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3.4 MRC SCORING (PAPER III) 
The MRCs for Paper III were evaluated by two observers, a senior consultant 
radiologist and a senior consultant hepatobiliary surgeon, and reported as consensus. 
The observers were blinded to the patients clinical parameters and outcome of the 
DHCE-MRI. The biliary tree, divided into the extrahepatic (CHD and CBD) and 
intrahepatic ducts (sectional and left and right hepatic ducts), were described and  
 
Table 8: Scoring system for bile duct changes as observed on MRC 
Score Parameter 
0 Normal, dilated or isolated stricture <50% 
1 Isolated stricture ≥50% or diffuse stricturing 
2 Beading 
3 Non-visualization 
 
graded as shown in Table 8. This system has previously been used in a scintigraphic 
study on segmental liver function and bile flow in PSC124. Due to the limitations of 
MRC in depicting fourth generation (segmental) intrahepatic bile ducts in PSC189, 190, 
the segmental ducts were not included in these calculations. The bile flow path for each 
segment was described by adding the scores of the ducts representing the biliary flow 
path for the specific segment, resulting in a score representative of the total downstream 
biliary obstruction for that particular segment. 
 
3.5 SIMULATIONS 
3.5.1 Paper I: Deconvolution simulations 
A numerical simulation comparing FA with appended tail (FA+tail) and TSVD for DA 
was performed. Ideal input and impulse functions were constructed from gamma 
variate functions 191. Curve shapes as similar as possible to those acquired in vivo were 
achieved by constructing mean input and impulse curves from data obtained in the 
study, and fitting these with a sum of two gamma variate functions. The input and 
impulse functions were then convoluted to find the response function, as shown in 
Equation 2. Different amounts of normal-distributed noise were applied to the response 
and input function respectively, to simulate different levels of SNR. DA was then 
applied using the two different techniques. The appended tail in the FA+tail technique 
was set to be three times the length of the simulation data. The truncation threshold in 
the TSVD technique was fixed at c=0.07. Simulations were performed 1000 times for 
each SNR level. HEF was calculated as described above and standard deviations of the 
results for the two methods were calculated. Simulations were performed using in-
house software written in MATLAB® (Mathworks, Michigan, USA). 
 
3.5.2 Paper IV: Hepatectomy simulations 
A left-sided hemihepatectomy (segments 2, 3 and 4) was simulated and post-operative 
remnant liver function (RLF) as predicted by global assessment and segmental 
assessment compared. This was done for 10 cirrhotic patients and 10 healthy 
volunteers. The RLF as predicted by an arbitrarily chosen global liver function test was 
calculated by deducting the percentage of the total hepatocyte extraction capacity 
(HEFml) equivalent to the percentage of the volume liver resected. For the simulation 
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of the RLF prediction based on segmental functional assessment, the HEFml of the 
remaining liver segments as calculated by DHCE-MRI were added. For example, if 
resection implied removal of 45% of the liver volume, the predicted RLF using global 
assessment was calculated as being 55% of the total liver function, whereas the 
measured function in HEFml of segments 1, 5, 6, 7, and 8 was added for the segmental 
DHCE-MRI-based prediction of RLF. 
 
3.6 STATISTICAL ANALYSES 
In all studies, STATA 10 (StataCorp, 4905 Lakeway Drive, College Station, Texas 
77845 USA), was used for the statistical analyses. In Paper I, GraphPad Prism 5 
(GraphPad Software INC, La Jolla, CA, USA) was used in addition to STATA 10. 
A two-sided significance threshold was set to α=0.05 in all studies. 
 
3.6.1 Paper I 
Descriptive statistics were used for presentation of HEF and irBF. The study yielded 
180 paired observations for HEF and irBF (20 subjects with 9 segmental registrations 
each and each subject analysed with both TSVD and FA+tail), and the median HEF 
and irBF for the two methods of DA were compared using the non-parametric 
Wilcoxon matched pairs test. The SD of HEF results from the two methods were 
compared using the variance ratio test (also known as the F-test). 
 
3.6.2 Paper II 
The results of the segmental calculations for quantitative and semi-quantitative 
parameters were presented as medians (with minimum and maximum) together with 
the global median for all studied parameters. Results were compared using the non-
parametric Mann-Whitney U-test. For the parameters where a significant difference in 
global median was observed, test for trend across ordered groups was used to assess the 
association between the CPS and MELD-score and the specific parameter. For these 
calculations, the controls were assigned a dummy value of 4 for CPS, and 5 for the 
MELD-score. This is one unit less than the lowest possible score in these models. The 
Mayo risk score was regarded as a continuous variable and the Spearman rank 
correlation was used instead, without assigning a dummy value for the controls. In 
those parameters where a significant difference between groups in global median was 
seen, Spearman rank correlation was also used for correlating the specific parameter to 
age in the patient group. Likewise, using the Mann-Whitney u-test, the outcome of the 
same parameters in the control group was compared, using gender as the independent 
variable.  
 
3.6.3 Papers III and IV 
Descriptive statistics were used for presentation of the liver function parameters. The 
non-parametric Mann-Whitney U-test was used to compare results regarding the liver 
function parameters and liver volumes, since a normal distribution could not be 
assumed. When comparing the median HEF of the right and left liver lobes, the 
Wilcoxon matched-pairs test was used. The distribution of differences between 
segmental function and volume (Adiff% and Rdiff) for patients and controls was 
compared using the variance ratio test (F-test). Correlations between liver function 
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parameters and clinical scores, including the MRC scores in Paper III, were assessed 
using Spearman rank correlation. In Paper IV, receiver operating characteristic (ROC) 
analysis was used to identify the optimal discriminating cut-off levels for the liver 
function parameters. 
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4 RESULTS 
4.1 RESULTS PAPER I 
The result of the DA simulation is shown in Table 9 as a SD comparison. TSVD 
performed significantly better than FA+tail at almost all SNR levels, except at SNR 
levels 6 and 15. 
 
 Table 9: Result of the simulation comparing TSVD and FA+tail 
SNR TSVD SD1 FA+tail SD1 p-value2 
6 0.116 0.122 p=0.059 
8 0.087 0.100 p<0.05 
10 0.070 0.078 p<0.05 
12 0.060 0.067 p<0.05 
15 0.050 0.051 p=0.27 
20 0.035 0.039 p<0.05 
25 0.027 0.030 p<0.05 
30 0.024 0.026 p<0.05 
35 0.020 0.022 p<0.05 
40 0.018 0.020 p<0.05 
45 0.016 0.017 p<0.05 
50 0.014 0.016 p<0.05 
70 0.010 0.011 p<0.05 
1) n = 1000 in both groups; 2) Variance ratio test 
 
 
The mean ROI size was 31.9 (SD 21.6) voxels. Summary statistics of HEF and irBF 
with the two DA methods are shown in Table 10, and presented graphically in Figure 
10, together with the distribution of HEF and irBF on the segmental level. 
 
 
Table 10: Summary statistics for HEF and irBF 
 HEF: TSVD 
HEF: 
FA+tail  
irBF: 
TSVD 
irBF: 
FA+tail  
       Mean 0.210 0.214  0.242 0.241  
Median 0.201 0.205 (p=0.086)1 0.240 0.239 (p=0.51)1 
Minimum 0.088 0.081  0.143 0.150  
Maximum 0.443 0.446  0.333 0.351  
Range 0.355 0.365  0.189 0.201  
SD 0.0512 0.0572 (p=0.068)2 0.0430 0.0400 (p=0.84)2 
CV 24.3% 26.7%  17.7% 16.6%  
1) Wilcoxon matched-pairs test 2) Variance ratio test 
CV=coefficient of variation 
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There were no significant differences in the overall median values of HEF or irBF 
calculated with the two DA methods (p=0.086 for HEF and p=0.51 for irBF). However, 
TSVD yielded a smaller SD and CV, although the difference in SD was not statistically 
significant (p=0.068 for HEF and p=0.84 for irBF). 
 
Parametric maps of HEF and irBF for a slice above the horizontal inter-segmental plane 
of the liver in one test subject are shown in Figure 11. HEF values above 0.7 and irBF 
above 1 were regarded as artefacts and excluded. HEF and irBF values are presented as 
percentages on a scale from 0 to 100%.  
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4.2 RESULTS PAPER II 
The results for the PBC patients compared to the healthy control group regarding 
median levels of the quantitative functional parameters on a segmental and global level 
are presented in Table 11. In a majority of segments, median HEF and MTT 
measurements were significantly lower in PBC patients compared to healthy 
volunteers. This difference was also observed for the global medians regarding HEF 
and MTT. With the exception of one segment (IVa), no significant differences between 
the groups were found in segmental or global medians for irBF. 
 
 Table 11: Segmental and global median results for quantitative and semi-quantitative 
functional parameters 
 HEF  irBF  MTT (s) 
 Controls PBC p*  Controls PBC p*  Controls PBC p* 
            S I 0.18 0.16 p=0.14  0.26 0.27 p=0.59  486 368 p=0.06 S II 0.21 0.16 p<0.05  0.22 0.23 p=0.20  562 351 p<0.05 S III 0.19 0.14 p=0.07  0.23 0.23 p=0.61  494 393 p=0.16 S IVa 0.20 0.16 p=0.07  0.22 0.25 p<0.05  485 369 p<0.05 S IVb 0.17 0.15 p=0.11  0.22 0.25 p=0.08  524 369 p<0.05 S V 0.21 0.16 p<0.05  0.25 0.28 p=0.37  521 379 p=0.05 S VI 0.20 0.16 p<0.05  0.27 0.28 p=0.31  509 350 p<0.05 S VII 0.22 0.19 p<0.05  0.26 0.28 p=0.76  479 399 p=0.10 S VIII 0.22 0.17 p<0.05  0.25 0.25 p=0.31  536 350 p<0.05 
            Global 0.20 0.16 p<0.05  0.24 0.25 p=0.35  503 363 p<0.05 
 
 Cmax  tmax (s)  t1/2 (s) 
 Controls PBC p*  Controls PBC p*  Controls PBC p* 
            
S I 0.533 0.581 p=0.41  1500 2400 p<0.05  12591 13305 p=0.57 
S II 0.473 0.480 p=0.61  1950 1800 p=0.68  12858 15898 p=0.82 
S III 0.451 0.455 p=0.79  1800 2400 p=0.08  11298 9062 p=0.63 
S IVa 0.459 0.539 p=0.33  1230 2250 p=0.24  15491 13162 p=0.48 
S IVb 0.448 0.526 p=0.12  1800 2550 p=0.07  14018 11902 p=0.96 
S V 0.574 0.600 p=0.85  2100 2550 p=0.28  20609 13019 p<0.05 
S VI 0.574 0.611 p=0.44  2100 2550 p=0.27  18595 22738 p=0.51 
S VII 0.557 0.607 p=0.35  1950 2700 p=0.25  20755 15889 p=0.57 
S VIII 0.553 0.555 p=0.70  2130 2100 p=0.80  23387 10773 p<0.05 
            Global 0.537 0.570 p=0.64  1950 2250 p=0.16  17697 14133 p=0.41 
*Mann-Whitney U-test 
 
The results for the semi-quantitative parameters are shown in Table 11. No significant 
differences were observed on the global level for any of these parameters. It was noted 
that the minimum value of tmax in the PBC group for all liver segments except segment 
I occurred as early as 120 s after injection of the tracer (not shown in Table 11). This 
means that the relative signal intensity in these segments peaked when the intravascular 
bolus of the tracer passed, and that very little tracer was subsequently extracted. 
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Since global medians of HEF and MTT, as well as medians for a majority of segmental 
values for these parameters differed significantly between the patient and control 
groups, further analyses were performed regarding the impact of disease severity on 
these parameters. As seen in Figure 12, MTT and HEF decreased significantly with 
increasing severity of liver disease as estimated with the CPS and MELD-score. There 
were no significant correlations between HEF and the Mayo risk score (Spearman´s rho 
= 0.242, p=0.448) or MTT and the Mayo risk score (Spearman´s rho = -0.32, p=0.308).  
 
 
To assess whether age influenced the results in the patient group, HEF and MTT were 
correlated to age, but no significant associations were found (Spearman rho=0.242, 
p=0.45 and rho=0.344, p=0.27 respectively). In the control group, gender was not 
found to be a substantial confounder, since neither the median HEF, nor the median 
MTT for men and women differed significantly (p=0.11 and p=0.76, Mann-Whitney U-
test). 
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4.3 RESULTS PAPER III 
When calculating the DA-derived parameters in the PSC group, TSVD produced 
artefacts (as previously defined) in 22% of the voxels compared to 2% for the FA+tail 
method. Among controls, the corresponding numbers were 20% and 1% respectively. 
Due to these results, only data from the FA+tail method were used in the further 
analysis of the results. The failure rate for FA+tail did not differ significantly between 
patients and controls (p=0.17). 
 
The relation between the quantitative functional parameters and liver volume 
measurements in patients and controls are shown in Table 12, where no statistically 
significant differences between the groups were found. 
 
 Table 12: Results of quantitative liver function and volume analysis 
 
Controls  PSC patients 
        
 
Median (Min-Max)  Median (Min-Max) p-value*        Total liver volume 
(ml) 1496 (1037-1934)  1564 (1101-1800) 0.59 
       Total hepatocyte 
volume (ml) 1321 (958-1664)  1386 (985-1629) 0.31 
         HEFml (Total liver 
function) 289 (191-475)  270 (182-425) 0.85 
         Median global HEF 0.23 (0.16-0.29)  0.21 (0.09-0.29) 0.24          Median global irBF 0.52 (0.43-0.64)  0.48 (0.34-0.59) 0.07          Median global MTT 789 (483-2292)  596 (351-1109) 0.07 
* Mann-Whitney U-test 
  
A significantly larger variance for Adiff% (3.82 versus 0.66) and Rdiff (0.032 versus 
0.006) was noted among patients compared to controls (p<0.05 for both parameters), 
indicating a more non-homogeneous distribution of function in the liver parenchyma in 
the PSC group compared to healthy controls. The uneven distribution of function in one 
patient with segmental disease is illustrated in the parametric maps presented in Figure 
13. This particular patient showed non-visualization of the sectional ducts to segments 
II-III-IVa-IVb, and also non-visualization of the left main hepatic duct. 
 
The variations in function and volume inflicted by disease are also illustrated in Figure 
14, where the function and volume of the right and left hemilivers in the two groups are 
presented.  
 
Cholangiographic findings indicated diffuse intrahepatic disease in all patients and 8 
(67%) patients had combined intra- and extrahepatic disease. The correlations between 
the cholangiographic findings and segmental functional parameters are displayed in 
Table 13. There was a statistically significant negative correlation between the added 
biliary scores and the segmental median HEF and irBF. 
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Table 13: Correlation between clinical and cholangiographic scores and 
liver functional parameters 
  
Segmental 
median HEF 
Segmental 
median irBF 
Segmental 
median MTT 
     
Sectional ducts rho -0.16 -0.16 0.01 p 0.11 0.12 0.93 
     
Main hepatic ducts  
(left & right) 
rho -0.21 -0.51 -0.20 
p <0.05 <0.05 <0.05 
     
CHD rho -0.20 -0.43 -0.34 p <0.05 <0.05 <0.05 
     
CBD rho -0.04 -0.10 0.25 p 0.72 0.31 <0.05 
     
Sum of downstream 
obstruction 
(sectional to CBD) 
rho -0.24 -0.45 -0.07 
p <0.05 <0.05 0.48 
    
 
  HEFml 
Global 
median 
HEF 
Global 
median 
irBF 
Global 
median 
MTT 
  
Child-Pugh 
score 
rho 0.02 -0.14 0.21 0.07 
p 0.96 0.67 0.52 0.83 
  
MELD rho -0.03 -0.14 0.37 0.55 p 0.92 0.67 0.24 0.06 
  
Mayo risk score rho -0.85 -0.80 -0.68 -0.20 p <0.05 <0.05 <0.05 0.53 
 
rho=Spearman rho, CHD=common hepatic duct  
p=p-value CBD=common bile duct 
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The correlations between the CPS, MELD and Mayo risk scores and global liver 
function parameters are presented in Table 13. A strong and significant negative 
correlation between the Mayo risk score and the total liver function expressed as 
HEFml, global median HEF and global median irBF was found. No significant 
correlation between Mayo risk score and global median MTT was found, nor were 
there any significant correlations between the global liver function parameters and the 
CPS and MELD-scores. 
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4.4 RESULTS PAPER IV 
The results of liver volume measurements and functional parameters in the two groups 
are shown in Table 14. There were no significant differences regarding total liver 
volume, but when vascular voxels were subtracted, the patient group had a significantly 
larger parenchymal volume, despite the fact that the overall parenchymal function 
expressed in HEFml was significantly lower. Also, the median liver HEF was 
significantly lower among patients, indicating lower parenchymal functional capacity 
per volume unit. The median MTT was significantly shorter in the patient group but 
perfusion assessed as irBF did not differ significantly between the groups. The semi-
quantitative parameter LSER was also significantly lower in the patient group at all 
studied time-points as illustrated in Figure 15, where the results are presented according 
to Child-Pugh class, and compared to controls. 
 Table 14: Results of liver function and volume analysis 
 
Controls  Patients   
 
Median (min-max)  Median (min-max) p-value
* 
 Total liver volume 
(ml) 1496 (1037-1934)  1577 (1357-1886) p=0.29 
Parenchymal volume 
(ml) 1256 (915-1692)  1435 (1225-1774) p<0.05 
       
Total functional 
capacity (HEFml) 283 (112-412)  171 (53-341) p<0.05 
Global median HEF 0.22 (0.11-0.28)  0.09 (0.02-0.20) p<0.05 Global median irBF 0.52 (0.43-0.63)  0.48 (0.31-0.74) p=0.17 Global median MTT 789 (477-1318)  453 (203-686) p<0.05 
       
LSER (10min) 2.3 (1.5-3.1)  1.3 (0.8-1.6) p<0.05 
LSER (20min) 3.4 (2.4-5.0)  1.8 (1.0-2.6) p<0.05 
LSER (30min) 5.7 (4.0-24.6)  2.0 (1.2-3.3) p<0.05 
LSER (45min) 7.2 (3.1-18.8)  2.4 (1.3-4.2) p<0.05         
*=Mann-Whitney U-test; LSER=liver-spleen enhancement ratio at corresponding time-points 
 
Table 15 displays the correlations between the liver function parameters obtained and 
liver disease grade as assessed by the CPS and MELD-score. Total liver functional 
capacity, median HEF, irBF and LSER at all studied time-points had significant 
correlations with the CPS. The MELD-score had negative and significant correlations 
with total liver function, median HEF and LSER at 45 min, but the LSER at the other 
time-points did not correlate with MELD. MTT did not correlate significantly with the 
scoring models used in this study. 
 
The distributions of absolute and relative differences (Adiff% and Rdiff) in segmental 
function and volume of the two groups differed significantly with a larger variance for 
Adiff% (7.1 vs. 0.61) and Rdiff (0.052 vs. 0.006) among patients compared to controls 
(p<0.05 for both parameters). The distributions are presented in Figure 16. 
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Table 15: Correlation of scoring models and liver function parameters  
 CPS   MELD  
 
Spearman 
rho 
p-
value  
Spearman 
rho 
p-
value 
      Total functional capacity (HEFml) -0.72 p<0.05  -0.76 p<0.05 Global median HEF -0.80 p<0.05  -0.73 p<0.05 Global median irBF 0.76 p<0.05  0.55 p=0.10 Global median MTT -0.26 p=0.46  0.05 p=0.88 
      LSER (10min) -0.74 p<0.05  -0.58 p=0.10 LSER (20min) -0.76 p<0.05  -0.63 p=0.07 LSER (30min) -0.72 p<0.05  -0.55 p=0.12 LSER (45min) -0.79 p<0.05  -0.75 p<0.05       
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The results of the simulated hemi-hepatectomy are presented in Table 16. Global liver 
function assessment overestimated the remnant liver function in 9 out of 10 patients by 
as much as 9.3% in absolute numbers (median -3.5% (range -9.3–3.5%)). 
 
 Table 16: Results of simulated left-sided hemihepatectomy 
Patient /  
CPC 1A 2A 3B 4A 5B 6B 7C 8A 9B 10B 
           Total liver 
function   
(HEFml) 
341 210 174 330 82 169 115 262 53 168 
Volume of 
resection (%) 55 52 46 37 56 51 48 46 45 30 
Predicted RLF 
(HEFml) 155 102 93 208 36 83 60 142 29 118 
Actual RLF 
(HEFml) 142 94 93 220 29 69 57 140 27 115 
Predicted RLF 
(%) 45.4 48.5 53.6 63.1 44.4 49.3 52.4 54.3 54.7 70.3 
Actual RLF 
(%) 41.6 44.7 53.3 66.6 35.2 40.8 50.0 53.5 50.6 68.6 
Difference  
(actual-predicted) -3.8 -3.8 -0.3 3.5 -9.3 -8.5 -2.4 -0.8 -4.1 -1.7 
           Control  1 2 3 4 5 6 7 8 9 10 
           Total liver 
function 
(HEFml) 
229 266 353 269 383 219 215 381 260 345 
Volume of 
resection (%) 40 26 37 35 28 38 32 32 37 31 
Predicted RLF 
(HEFml) 138 196 220 175 274 137 146 258 165 239 
Actual RLF 
(HEFml) 139 201 228 178 275 139 149 259 171 236 
Predicted RLF 
(%) 60.2 73.8 62.5 64.9 71.5 62.4 67.7 67.7 63.2 69.3 
Actual RLF 
(%) 60.8 75.7 64.6 66.0 71.8 63.2 69.5 67.9 65.7 68.5 
Difference  
(actual-predicted) 0.6 1.9 2.1 1.2 0.3 0.8 1.8 0.2 2.5 -0.7 
CPC = Child-Pugh class RLF = remnant liver function 
   
  
   49 
The cut-off levels and their ability to discriminate between patients and controls in this 
study are presented in Table 17 with generally good or excellent accuracy for all the 
studied parameters. 
 
 Table 17: ROC analysis 
Controls and Child Pugh A versus Child Pugh B and C 
 AUROC 
Cut-
off Sensitivity Specificity Accuracy LR+ LR- 
        Liver function 
(HEFml) 0.97 209 95.8% 100.0% 96.7%  0.04 
Global median 
HEF 1 0.11 100.0% 100.0% 100.0%   
LSER 10 0.97 1.31 100.0% 83.3% 96.7% 6.00  LSER 20 0.99 1.88 100.0% 83.3% 96.7% 6.00  LSER30 0.99 2.22 100.0% 83.3% 96.7% 6.00  LSER 45 1 2.43 100.0% 100.0% 100.0%   
 
       
Controls versus patient group 
 
AUROC Cut-off Sensitivity Specificity Accuracy LR+ LR- 
        Liver function 
(HEFml) 0.79 215 90.0% 70.0% 83.3% 3.00 0.14 
Global median 
HEF 0.94 0.18 95.0% 80.0% 90.0% 4.75 0.06 
LSER 10 0.99 1.67 95.0% 100.0% 96.7%  0.05 LSER 20 0.98 2.48 95.0% 90.0% 93.3% 9.50 0.06 
LSER 30 1 4.01 100.0% 100.0% 100.0%   LSER 45 0.98 4.63 90.0% 100.0% 93.1%  0.10 
AUROC= area under receiver operator characteristic curve 
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5 DISCUSSION 
This thesis presents the concept of an imaging-based liver function test with a 
hepatocyte-specific MRI contrast agent as tracer, and dynamic MRI as the sampling 
tool. The tracer used, Gd-EOB-DTPA or gadoxetic acid, is actively taken up by 
functioning hepatocytes through the OATP and NTCP enzyme systems. This is a 
property shared at least in part with ICG and the IDA compounds currently used in 
clinical practice for assessing liver function. Conceptually, the uptake of Gd-EOB-
DTPA into the hepatocyte should therefore correspond to the same aspects of liver 
function that can be assessed by ICG clearance and functional HBS. That the uptake of 
Gd-EOB-DTPA actually reflects aspects of liver function has been shown in several 
previous studies, both in human and animal subjects167, 178-188, 192, 193. 
 
In this work, a method is proposed where the sampling of contrast agent concentrations 
is done in the blood pool and liver parenchyma. The resulting SIr-curves are used to 
quantify tracer kinetics for assessment of regional and global liver perfusion and 
hepatocellular tracer extraction capacity. It utilizes the concept of DA to correct the 
liver parenchymal enhancement response for the constantly changing concentration of 
tracer in the inflow to the liver. DA has earlier been described as a tool for 
quantification of tracer kinetics in quantitative studies of the brain and kidney, as well 
as in scintigraphic assessment of liver function117, 121, 138, 139, 142, 144, 145, 147, 148, 194-197. 
There is only one previously published animal study where MRI and DA were used to 
assess the hepatic uptake of Gd-EOB-DTPA.180. 
 
The studies presented here show that DHCE-MRI with or without DA can be used in 
human subjects to calculate several liver function parameters on both a global and 
segmental level, as well as global and segmental liver volumes. 
 
Traditional semi-quantitative parameters (Cmax, tmax, t1/2) were found to be of limited 
value and they failed to distinguish patients from normal volunteers. Being easily 
accessible, without the need for advanced post-processing for calculation, they are 
often used to describe the pharmacokinetic properties of a system. These parameters are 
perhaps more intuitive and more easily understood than the DA-derived parameters, but 
they have to be interpreted with caution. A high Cmax is usually regarded as a good 
extraction capacity of the parenchyma, but can also be the result of virtually non-
functioning liver parenchyma with arterialization due to cirrhosis or inflammation and a 
quick and high vascular peak. Furthermore, failure to transport a test substrate into the 
bile canaliculi or stasis in the intrahepatic bile ducts might also give a high Cmax, giving 
the notion of a well-functioning parenchyma. A short t1/2, calculated from a time-
enhancement curve generated by a parenchymal ROI or voxel is generally interpreted 
as good tracer excretion. However, in parenchyma with no extraction capacity, where 
the tracer-derived signal is mainly from the intrahepatic blood pool, a short t1/2 will be 
observed if the serum half-life of the tracer is short. Furthermore, a long t1/2 that 
generally would be interpreted as decreased parenchymal function could be the result of 
activity measured in obstructed bile ducts or intracellular sequestration of tracer in a 
patient with normal tracer uptake but abnormal biliary excretion. 
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With liver segmentation and a voxel-based approach, segmental results for HEF, irBF 
and MTT, as well as total parenchymal and segmental liver volumes could be 
calculated. Furthermore, both the total hepatic and segmental extraction capacities of 
Gd-EOB-DTPA assessed in HEFml could be obtained. The lower HEF and HEFml 
observed in PBC and cirrhotics compared to the healthy controls can be explained 
either by a reduced functional hepatocyte mass or hepatocytes with less capacity to 
transport Gd-EOB-DTPA across the hepatocyte membrane. The shorter MTT seen 
among cirrhotics and in the PBC group is probably due to a lower hepatic extraction 
and a larger proportion of the tracer being washed out of the system through the 
vascular outflow. In healthy livers, the MTT is probably longer due to uptake into 
hepatocytes, intracellular transport and subsequent biliary excretion, a process that 
doubtless is more time-consuming. There were no significant differences regarding 
irBF between controls and patients with PBC, PSC or cirrhosis. The significant positive 
correlation between irBF and CPS observed in cirrhotics could possibly be the result of 
increasing arterialization of perfusion in cirrhotic parenchyma, known to increase with 
increasing disease severity198. Conversely, irBF showed a significant negative 
correlation with the Mayo risk score in PSC patients. 
 
Total segmental ―downstream‖ bile duct obstruction as defined by the scoring system 
used was also found to negatively correlate with HEF and irBF, but not with MTT. This 
finding indicates that segments with a more pronounced biliary stasis had less 
extraction capacity and thus less function as defined by this method. This finding also 
replicates earlier findings from scintigraphic studies on biliary obstruction in PSC 
where the same scoring system was used, but segmental liver function was semi-
quantitatively assessed124. On a total liver level it has been shown that uptake of Gd-
EOB-DTPA is impaired in patients with impaired liver function167, 183-188. This work 
suggests that DHCE-MRI also has the capability to detect segmental variations in 
function. 
 
The ROC analysis performed in cirrhotics yielded cut-off values for total liver function, 
median HEF and median LSER at all time-points that showed good to excellent 
accuracy regarding separation of the groups in the analysis. It was possible both to 
distinguish controls from the entire patient group, as well as patients with severely 
impaired liver function (CPC B and C) from those with normal or mild liver disease 
(controls and CPC A). The rationale behind this latter way to categorize the groups was 
that the life expectancy in CPC A is marginally less than in healthy controls, whereas in 
CPC B and C it is markedly worse. 
 
In the fourth study the less computationally demanding semi-quantitative parameter 
LSER was also studied, and it was shown to differ significantly between controls and 
the cirrhosis group. LSER at all studied time points correlated with CPS, and performed 
well in the ROC analysis. It should be noted that a significant difference in LSER was 
evident as early as 10 minutes post contrast injection. 
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5.1 DISTRIBUTION OF LIVER FUNCTION 
There is ample data showing that liver function is heterogeneously distributed within 
the liver, both in healthy as well as in diseased parenchyma. This work supports these 
earlier results. 
 
5.1.1 Normal liver 
Scintigraphic studies assessing liver function have suggested an inherently different 
uptake capacity of tracers in the left and right hemilivers in healthy subjects, a finding 
that was replicated in this 
work199, 200. When using voxel-
based analysis, the median 
HEF for the left and right 
hemiliver voxels among 
healthy controls was 0.21 and 
0.23 respectively, which was 
statistically significant 
(p<0.05). This difference was 
also observed in the ROI-based 
analysis of Paper I (results not 
shown). Also presented here 
are the RE/time-curves-
(equivalent to SIr/time curves) 
of the individual segments for the healthy volunteers of Paper I, showing a substantial 
difference in the uptake pattern of Gd-EOB-DTPA between the left (S II, III, IV) and 
right hemilivers (S V, VI, VII, VIII).  
 
5.1.2 Diseased liver 
In case of liver parenchyma being affected by disease, the situation regarding 
distribution of function might be even more complex. Histopathological studies of liver 
biopsies from diseased parenchyma have repeatedly shown non-homogeneous 
distribution of disease, be it fibrosis, cirrhosis, steatohepatitis or steatosis34, 35, 201-204. 
Several studies where HBS with IDA and GSA were used to evaluate regional liver 
function have confirmed that not only are histopathologic findings variable within the 
liver but as could be expected, function also seems to be non-homogeneously 
distributed120, 124, 205-208. It is also well-known that the cirrhotic liver parenchyma 
undergoes morphologic changes with hypertrophy of the left hemiliver and caudate 
lobe, and hypotrophy of the right hemiliver. Using 99mTc-GSA, Matsuzaki et al found 
that in liver cirrhosis the parenchyma of the left hemiliver seems to be less functionally 
affected by injury with a more preserved function per volume unit compared to the 
right hemiliver207.  
 
The results of the voxel-based analysis of liver function in PSC and cirrhotics 
confirmed these earlier findings of significantly more heterogeneous distribution of 
liver function in patients with liver disease, and a relative hypertrophy of the left 
hemiliver. Furthermore, in the cirrhosis group median HEF was found to be higher in 
the left liver (0.08 for the right liver and 0.11 in the left (p=0.06)), suggesting that the 
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quality of the hypertrophied left liver is slightly superior to that of the right, replicating 
the findings of Matsuzaki et al207. 
 
In healthy controls, the left hemiliver accounted for approximately 34% of the volume 
and 33% of the function, and the right hemiliver accounted for 64% of the volume and 
65% of the function, with volume and function being quite closely related. In this 
situation with normal liver parenchyma, prediction of post-operative RLF using a 
segmental liver function test probably offers no major advantage compared to the 
current clinical practice of using a combination of volumetry and a global liver function 
test. In our simulation of a left-sided hemihepatectomy in this group of healthy controls, 
the differences in predicted liver function were negligible. 
 
In patients with diseased liver parenchyma the situation is different. Global liver 
function tests, such as ICG clearance or the LiMax test cannot account for regional 
differences in liver function, making prediction of postoperative RLF of diseased liver 
parenchyma uncertain. This was also shown to be the case in this work when a left 
hemihepatectomy was simulated. The observed maximum difference between predicted 
and actual remnant liver function assessed with DHCE-MRI was 9.3%. If this had been 
a real case and these figures were true, such an error in prediction could be the 
difference between an uneventful postoperative course and postoperative liver failure 
with a possible fatal outcome. 
 
5.2 LIMITATIONS AND ARTEFACTS 
5.2.1 Study subjects 
5.2.1.1 Controls 
The same control group was used in all studies. The images were re-analyzed and the 
DHCE-MRI derived parameters were recalculated for each study as described in the 
Materials and Methods sections. No quantitative liver function test was performed to 
confirm normal liver function. However, none of the participants had a history of 
hepatobiliary disease, liver surgery or overconsumption of alcohol, and no abnormal 
serum LFTs were detected. One can therefore with reasonable confidence conclude that 
the reference group consists of subjects with liver function that can be regarded as 
normal. 
 
One concern regarding the DHCE-MRI derived quantitative liver function parameters 
studied is the relatively large range in the results that was observed among healthy 
controls. The variation was substantial both intra- and interindividually, which in part 
could reflect actual inter-individual differences in the hepatic elimination capacity of 
Gd-EOB-DTPA, since it is known that hepatic elimination of pharmacological agents 
has a large variation even among healthy individuals190. In addition, inter-individual 
variation in ICG clearance among healthy individuals has been shown to be substantial, 
and since Gd-EOB-DTPA and ICG to some extent have the same hepatocellular uptake 
mechanism, this normal inter-individual variation could also be the case for Gd-EOB-
DTPA96, 209. Furthermore, differences in diet or other life-style related factors prior to 
the examination could have influenced the results. Adjustments for confounders such as 
age, gender or body weight were not made, but previous studies of biliary excretion of 
 54 
Gd-EOB-DTPA have not found age, gender or BMI to significantly influence the 
hepatobiliary transit time of Gd-EOB-DTPA210. The intra-individual variation is 
probably to a substantial extent also due to imaging-related artefacts and imperfections 
in the method, as will be further discussed. 
 
5.2.1.2 Patients 
Patients with PBC, PSC and alcohol- and/or HCV-induced cirrhosis were used to study 
the effects of chronic and segmental liver disease on the outcome of DHCE-MRI. In all 
studies, the numbers of participating patients were relatively low, and especially scarce 
were patients with advanced disease. Both PBC and PSC are relatively rare diseases 
and patients with advanced disease generally undergo liver transplantation. In the PBC 
and PSC groups, designated scoring models were used to stage liver disease, but also 
the CPS and MELD-scores. The latter two have been shown to be of no prognostic 
value when applied in the absence of cirrhosis, and it is not clear how many of the 
participants had histological signs of cirrhosis, since no biopsies were performed. The 
usefulness and accuracy of the MELD and CPS in this setting can therefore be 
questioned. 
 
A major limitation in this work is that liver function was not quantitatively assessed 
using a reference method in the participating patients. Even though no particular test 
stands out as a generally accepted golden standard, ICG clearance is widely used and 
studied, especially in the context of liver surgery and is perhaps as close to a golden 
standard as one can get today. An obvious step will be to include ICG clearance or 
another quantitative liver function test in future studies applying DHCE-MRI. 
 
5.2.2 Image acquisition and parameter calculations 
5.2.2.1 Segmentation 
The way in which the liver was divided into segments in this work followed the 
generally accepted anatomical landmarks for segmentation. Defining segmental 
volumes by the drawing of straight lines through the liver volume is a method that 
could be regarded as crude. Segmentation using the actual vascular territories of the 
portal vein by following the division of its branches in the liver parenchyma gives a 
more functionally correct 
segmentation of the liver. 
Such a method has been 
developed by Fraunhofer 
MEVIS (Bremen, 
Germany)211. An example 
where the Fraunhofer 
MEVIS method to define 
the liver segments has been 
applied to dynamic 
acquisitions from this work 
is presented in Figure 18. 
The combination of this 
method for segmentation 
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together with a method for voxel-based liver function analysis could give a more 
realistic estimation of segmental volumes and function, and possibly more accurately 
predict postoperative RLF, if applied in the preoperative evaluation of candidates for 
liver surgery. 
 
5.2.2.2 Motion artefacts 
In dynamic imaging-based studies of abdominal organs, motion artefacts are known to 
be a challenge, mainly due to breathing. These artefacts can be reduced by acquisitions 
being obtained during breath-hold, or by using a way of triggering of the scanner so 
that images are always obtained at the same time-point in the respiratory cycle. In this 
work patient motion in the MRI scanner over time and inability of the participating 
subjects to hold their breath at exactly the same depth during each acquisition could 
have induced substantial artefacts in the images obtained. Motion artefacts were indeed 
noted, which could have the effect that a ROI placed in the parenchyma in one of the 
acquired volumes may not represent liver parenchyma in the volumes acquired at other 
time-points. Of course this is true also in a voxel-based analysis, and it is evident that 
motion artefacts will impact the results of the quantitative analysis. The use of 
triggering devices or post-processing with image registration algorithms for motion 
correction is a logical next step in the pursuit of improving the method and stability of 
the results. 
 
5.2.2.3 Partial volume effects 
Some of the variations in the functional parameters described in this work could be 
attributed to what is known as partial volume effects. Even though individual voxels are 
small, they will inevitably include varying volumes of non-hepatocyte tissue. 
Conceptually, a ROI or voxel containing a higher proportion of vessels would yield a 
higher irBF due to higher perfusion and a lower HEF since extraction only takes place 
in hepatocytes. The reverse 
would be the case in a voxel or 
ROI containing a higher 
proportion of hepatocytes. This 
is illustrated in Figure 19 
showing the ROI results from 
Paper I (TSVD derived), 
where HEF is plotted as a 
function of irBF (dotted lines 
denote the 95% confidence 
interval). A significant linear 
relationship between these 
parameters was observed. 
 
In an attempt to reduce the influence of partial volume effects, ROIs were placed 
avoiding major vascular structures and bile ducts as far as possible. In the voxel-based 
analysis, voxels with irBF above a user-defined threshold were omitted from analysis 
since they were regarded as mainly representing vascular tissue. 
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5.2.2.4 Choice of input function 
In studies where DA is applied, a well-defined and accurate input function is crucial for 
obtaining reliable results. As previously mentioned, the liver has a dual vascular supply 
with venous inflow from the portal vein contributing approximately 75% and arterial 
blood from the hepatic artery contributing the remaining 25%. In principle, an input 
function should be defined close to the organ studied. In the case of the liver, ideally a 
dual input function model representing the dual arterial and venous inflow should be 
used. The placement of the input function ROI is usually done manually, making it user 
or observer dependent, adding a factor of subjective decision-making to the method. 
Ideally, the input function should be automatically defined in the images, thereby 
eliminating a source of bias. 
 
In the first two studies, a ROI in the hilar part of the portal vein was used to define the 
input function. In terms of vascular flow a portal vein input function is more 
representative of the inflow of tracer than a ROI in the hepatic artery. Furthermore, the 
motion artefacts and limited image resolution in the studies made it impossible to 
define the hepatic artery in images other than the one or two acquired during the arterial 
phase. The aorta was not used to define the input function for two reasons. The first 
reason was that since the images were obtained in the transverse plane, inflow artefacts 
would have affected the input function. The second reason was that the short arterial 
peak with the first passage of contrast bolus would not have been optimally assessed 
with the temporal resolution used. This could have resulted in disturbing differences 
between subjects regarding maximum peak values in the input functions obtained. The 
portal inflow peak is somewhat more dispersed over time and the differences in the 
peak values observed were small. In the case of liver assessment, there is probably an 
advantage in using the portal vein, since the portal vein blood-flow is slower and with a 
direction in the x, y and z magnetic gradient field that makes it less susceptible to 
inflow artefacts compared to the aortic blood flow. A further disadvantage of using a 
hepatic artery input function is that approximately 50% of the arterial inflow of blood 
does not reach the hepatocytes, but rather supply the biliary tree with oxygenated 
blood, with a venous drainage into the hepatic veins and not the sinusoidal system26. 
 
In Papers III and IV the input function was defined by a ROI placed in the spleen. The 
strategy of using the spleen has shown an increase in the stability of the input function 
in conventional DCE-MRI using extracellular contrast agents 212. This is most likely 
due to the fact that the spleen is substantially larger and less prone to respiratory and 
patient movement artefacts compared to the portal vein. There might even be a 
physiological advantage in using the spleen to define the input function in DHCE-MRI. 
In the majority of subjects the spleen and the liver both receive their arterial supply 
from the celiac trunc 20, 213. Furthermore, the venous drainage of the spleen contributes 
significantly to the portal flow. Although not a perfect model, the spleen might to some 
extent represent the dual arterial and venous components of the blood supply to the 
liver. A theoretical disadvantage with this approach could be the effects on splenic 
blood flow from subclinical or manifest portal hypertension that could possibly 
influence the input function when patients with chronic liver disease are examined, and 
this method would also obviously not be possible in patients after splenectomy. 
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5.2.2.5 Signal intensity and contrast agent concentration 
Many would argue that the use of the words ―quantitative liver function analysis with 
MRI‖ is a contradiction of terms, since the signal that generates images in MRI is 
inherently non-quantitative but rather relative. For example, the same concentration of 
Gd-EOB-DTPA in liver and blood will result in different signal intensities due to 
inherently different native T1 of these tissues, as well as different r1 for Gd-EOB-
DTPA in blood and liver as previously described. For example, native T1 in liver has 
been reported to be 586 ms, T1 in the spleen 1057 ms and in blood 1262 ms214, 215. The 
signal intensity in a T1-weighted pulse sequence is proportional to the longitudinal 
relaxation rate (R1) that is given by Equation 15, where T10 denotes the native pre-
contrast T1 in the tissue: 
 
                     [Eq 15] 
 
From this equation and the T10 and r1 values from the literature previously described, 
the T1, at increasing concentrations of Gd-EOB-DTPA in blood, liver and spleen, can 
be calculated as shown in 
Figure 20. The maximum 
concentration in this 
figure, 0.12 mmol/L (mM), 
is the theoretical maximum 
plasma concentration in 
vivo, if the usual clinical 
dose of 0.1 ml/kg of Gd-
EOB-DTPA with the 
concentration 0.25 
mmol/ml is administered, 
and the distribution 
volume is 0.21 L/kg. As 
illustrated, T1 in the 
different tissues is not the 
same at equivalent concentration of Gd-EOB-DTPA, and therefore R1 and signal 
intensity will not be the same either. Signal intensity in a T1-weighted steady-state 
spoiled gradient-echo pulse sequence can be calculated using Equation 16: 
 
                                           [Eq 16] 
 
where S(t) is the signal at time t, S0 is the signal intensity from the fully relaxed system, 
TR is the repetition time and α is the flip angle. R(t) is the relaxation rate at time t, given 
that the concentration of tracer can be seen as a function of time, which is the case in 
dynamic MRI with Gd-based tracers. In this work, the concentration of Gd-EOB-
DTPA in a voxel or ROI was assumed to be proportional to the SIr as described in 
Equation 10. It has been shown that the relationship between signal intensity and 
contrast agent concentration is non-linear for gradient-echo pulse sequences used in T1-
weighted imaging. However, when T1-relaxation is within the range of 40 ms to 2600 
ms, the MRI signal using Gd-DTPA was shown to increase approximately 
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exponentially with shortened T1-relaxation216. Given the data from Figure 20, it can be 
assumed that T1 in all acquisitions in this work were within this range, making 
Equation 10 a reasonable approximation of contrast agent concentration. In this work 
the logarithmic relationship of Equation 9 was used to calculate the SIr as a surrogate 
for contrast agent concentration. In many studies the relationship between pre- and 
post-contrast signal intensity and contrast agent concentration is instead calculated as 
described in Equation 17: 
 
                      [Eq 17] 
 
Equations 16 and 9 and Equations 16 and 17 in combination can be used to calculate 
the SIr as a function of the concentration of Gd-EOB-DTPA in liver, spleen and blood, 
as shown in Figure 21. 
 
 
From this figure it can be assumed that the method chosen for this work (Equation 9) 
probably makes the relationship between contrast agent concentration and SIr slightly 
less linear than Equation 17. On the other hand, the difference in SIr for the same 
concentrations of tracer in different tissues of interest seems to be slightly less. 
 
5.2.2.6 DA-related matters 
The high failure rate of the TSVD method for DA in Papers III and IV seemingly 
contradicts the results from the simulations described in Paper I. Based on this paper 
DHCE-MRI using TSVD was regarded as the preferred method due to superior 
stability of the simulation results compared to the FA, and for being less 
computationally demanding. In that context, only standard deviations and not the 
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failure rates were assessed. In this material as a whole, FA+tail turned out to be 
superior to TSVD for DA in vivo. 
 
A static truncation threshold of c=0.07 was used in all deconvolutions where TSVD 
was applied. This threshold was arbitrarily chosen, but when other thresholds were 
applied, a larger variance was noted (unpublished material) and therefore the original 
threshold was used in the further studies. There are studies discussing the use of an 
automatically defined threshold, c, which has been shown to improve the performance 
of TSVD when used to assess brain perfusion196, 217. 
 
5.2.2.7 Acquisition time-frame 
The research protocol used in the first three studies was primarily designed to examine 
the liver enhancement well into the excretory phase of the contrast agent. Therefore an 
investigation time of at least 90 minutes was needed. Such a time-frame for image 
acquisition makes the method unpractical in terms of logistics and from a patient point 
of view. However, the mathematical model (DA) used to calculate the functional 
parameters only uses acquisitions obtained during the first 30 minutes (420-1800s). 
Therefore, the protocol in Paper IV was shortened to a total sampling time of 45 
minutes. Further shortening of the protocol seems feasible and a preliminary estimation 
is that a dynamic acquisition time of 30 minutes should suffice. If only the LSER is to 
be calculated, findings in this work indicate that image acquisition after 10 minutes is 
sufficient to detect differences between healthy controls and cirrhotic patients. Whether 
this is the case also in patients with mild chronic liver disease has not been evaluated in 
this work. One can note that imaging after 10-15 minutes, i.e. the hepatobiliary phase, 
is a common procedure in clinical practice when Gd-EOB-DTPA is used as the tracer. 
At this time-point sufficient tracer has usually been extracted by the liver parenchyma 
to allow characterization between lesions containing functioning hepatocytes and those 
that are devoid of hepatocellular function and tracer uptake. 
 
5.2.2.8 Pulse sequence and choice of tracer 
The pulse sequence used in the presented studies is a volumetric heavily T1-weighted 
standard clinical gradient-echo pulse sequence called THRIVE® (Philips), which was 
introduced in 2003. There are other commercially available pulse sequences from other 
manufacturers with similar performance, such as FAME®, LAVA® (GE Healthcare) 
and VIBE® (Siemens). Since the start of this project there has been further 
development in image acquisition techniques, and there are now pulse sequences with 
even faster volume acquisition available. The use of a more up-to-date pulse sequence 
would probably allow for better temporal and/or spatial resolution in the acquired 
volumes than was obtained in this work. 
 
There are other hepatocyte-specific contrast agents for liver MRI apart from Gd-EOB-
DTPA, one of them being Gd-BOPTA (MultiHance®, Bracco Imaging, Milano, Italy). 
Gd-BOPTA shows less liver uptake compared to Gd-EOB-DTPA with only about 2-
4% being eliminated through the biliary pathway, the rest being via renal excretion. 
Furthermore, it has substantially slower hepatic kinetics with a maximum enhancement 
in the liver parenchyma after 40-120 minutes compared to about 20 minutes for Gd-
EOB-DTPA, making it less suitable for tracer kinetics estimation157. Mangafodipir 
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trisodium, Mn-DPDP (Teslascan®, GE Healthcare, Milwaukee, USA) is a manganese 
(Mn) chelate developed for hepatobiliary imaging. The hepatocellular uptake is 
probably through the vitamin B6 system, and approximately 60% of the administered 
dose is excreted through the hepatobiliary pathway. The maximum signal intensity 
from the start of injection occurs after about 20 minutes218. Mn-DPDP is usually 
administered as a slow intravenous infusion over about 20 minutes, making it 
unsuitable for dynamic imaging. At present, Teslascan® is not commercially available 
in Sweden. 
 
There are also MRI contrast agents designed for the RES of the liver, such as 
Endorem® (Guerbet, France) and Resovist® (Bayer Schering Pharma, Berlin, 
Germany). They consist of small iron particles that are phagocytised by Kupffer-cells 
and since they are not extracted by hepatocytes, they cannot be used to assess 
hepatocellular function. 
 
5.3 CLINICAL SIGNIFICANCE 
Although the literature describes a multitude of methods for dynamic assessment of 
liver function, invasive as well as non-invasive, no single test stands out as a generally 
accepted golden standard. This is probably due to the fact that all tests described have 
their particular shortcomings, and no method has proven to be of undisputable benefit 
compared to others. Furthermore, the results of studies on liver function tests are often 
not using unanimously approved units of measurement and are not reported in a 
standardized fashion, and different definitions of outcome such as liver failure are 
frequent. This lack of agreement makes comparison between different studies difficult 
or impossible. The absence of a golden standard makes it hard to evaluate the possible 
benefits of a new method to assess liver function, since there is no generally agreed 
reference method to be used for comparison. 
 
In current practice MRI plays an important role in the management of PSC patients. For 
example, the diagnosis is frequently based on MRC findings and imaging-based 
screening of the PSC population is advised for the early detection of gallbladder 
carcinoma46. DHCE-MRI can be performed as an add-on to already existing MRI 
protocols with a moderate increase in total imaging time. According to current 
diagnostic criteria liver biopsy is not mandatory for the diagnosis of PSC or PBC. 
Nevertheless, it is frequently used for confirming the diagnosis and to rule out overlap 
between these diseases and AIH. The non-homogeneous nature of chronic cholestatic 
disease results in a significant risk of sampling error for grading of cirrhosis and 
fibrosis46, 219. Segmental functional data that identify the most affected parts of the liver 
could direct biopsies, thereby making histology more representative of disease activity 
and grade. Segmental DA-derived functional parameters were shown to correlate with 
the quantitative bile duct scores in PSC patients. That could open up the possibility of 
assessing the impact of radiologically detected biliary strictures on actual liver function, 
allowing more judicious selection of strictures for intervention. Furthermore, the result 
of endoscopic or percutaneous intervention aimed at strictures could be quantified, and 
the effect of novel medical treatments on parenchymal function and bile flow could be 
assessed. 
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Liver surgery has seen an unparalleled expansion and evolution during the last decades. 
Despite the tremendous advances in operative technique and perioperative care, 
postoperative liver failure continues to be a major cause of postoperative morbidity and 
mortality. In current clinical practice there is no consensus regarding the necessity of 
preoperative liver functional analysis, nor is there a unanimously preferred method. 
Decision-making is not infrequently based on a subjective judgment of what is 
regarded as a sufficient RLV, often incorrectly seen as being directly proportional to 
RLF. What the critical RLV is has not been scientifically evaluated, but in a recent 
survey of hepato-pancreato-biliary and transplant centres large variations in what was 
regarded as critical RLV after liver resection were found 103. For normal livers the 
critical RLV was 25% (range 15-40%) and for patients with cirrhosis 50% (range 25-
90%). The large range in what respondents regard as the critical RLV in patients with 
cirrhosis is striking and probably indicative of a wide spectrum in disease severity in 
the cirrhosis population, but also uncertainty regarding the state of the parenchyma, 
reflecting lack of confidence in the existing clinical and metabolic methods to evaluate 
liver function. The survey also showed large differences in the use of pre-operative 
quantitative metabolic tests to assess liver function. In the United States clinical 
assessment was favoured, often using scoring systems such as the CPS and Okuda 
classification 220. In the same study only 11% of North American centres used pre-
operative metabolic assessment, compared to 76% of Asian and 43% of European 
centres. 
 
Historically, underlying parenchymal liver disease in patients considered for liver 
resection was almost exclusively limited to cirrhosis in patients with resectable HCC. 
In current practice parenchymal dysfunction is encountered with increasing frequency 
in non-cirrhotic patients. Colorectal cancer liver metastases have, at least in Western 
countries, become the most common indication for liver resection. Chemotherapy is 
used with increasing frequency for down-staging or in the neo-adjuvant setting. 
Although not all agents have been studied, some have shown to be hepatotoxic, 
resulting in sinusoidal obstruction syndrome (SOS) and chemotherapy-associated 
steatohepatitis (CASH), associated with a higher morbidity and even higher mortality 
after surgery 7, 221, 222. Probably due to what is known as the obesity epidemic, NAFLD 
has become the most common chronic liver disease in the Western world. Between 
10% and 20% of the patients with NAFLD will progress to NASH, which may in turn 
lead to liver cirrhosis and HCC223, 224. Both chemotherapy-induced liver injury and 
metabolic syndrome-associated hepatic disease have been shown to be non-
homogeneously distributed within the liver 34, 201-203. 
 
Certainly, not all the patients included in this work would be candidates for liver 
resection, should an indication arise. The hepatectomy simulation does however 
demonstrate the potential danger of trusting the results of a global liver function test in 
patients with non-homogeneous parenchymal liver disease. Even if global tests are 
likely to become more sophisticated, maybe even giving information on multiple 
metabolic pathways, the results in this study argue strongly in favour of incorporating 
data on segmental liver function in the preoperative assessment of postoperative RLF. 
Patients considered for liver resection should not be subjected to unnecessary risks by 
overestimating RLF. Nor should patients that are in fact eligible for surgery be 
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excluded from potential curative treatment due to underestimation of their 
postoperative remnant functional capacity. 
 
With DHCE-MRI, one might have the long sought after ―one stop shop‖ for liver 
function assessment close at hand. MRI can provide detailed anatomical information on 
the biliary and vascular anatomy of the liver, oncological information including 
characterization of liver lesions, their number, size, and location as well as functional 
information regarding these lesions. From MR images, total and segmental liver 
volumes can be obtained for accurate volumetry. Furthermore, MRI can give 
information about fat and iron content of the liver parenchyma and theoretically, a MRI 
scan can be repeated an infinite number of times without known risk to the patient. 
With the addition of DHCE-MRI to the above applications, total and regional liver 
function can be added to the list of what is possible to achieve with MRI. 
 
To gain wide acceptance, a liver function test should not only be safe, accurate and 
reproducible, but also it needs to carry a reasonable cost and be readily available. Most 
importantly, a test must provide added information which will impact clinical decision-
making. DHCE-MRI fulfils at least some of these criteria. It is safe and non-invasive 
and MRI scanners are often available at larger hepatology institutions and in centres 
where liver surgery is performed. This work was done on a standard 1.5T scanner with 
a standard clinical pulse sequence. Gd-EOB-DTPA is commercially available as 
Primovist® in large parts of the world, including most countries in Europe, Asia and 
USA. There are data showing that Gd-EOB-DTPA-enhanced MRI is superior to 
contrast-enhanced CT in detecting small colorectal cancer metastases, and also superior 
regarding characterization of small HCC nodules, and that the use of MRI in this 
context is probably cost-efficient225. How accurate and reproducible DHCE-MRI is in 
preoperative liver function assessment and other clinical settings, and what the added 
value might be, has to be clarified in future studies. 
 
5.4 FUTURE STUDIES 
The aim of future studies in the area of DHCE-MRI for liver function assessment can 
be foreseen to have two major directions. The first will deal with the method itself, and 
there are numerous unanswered questions that have to be further addressed. These 
include issues like: 
 
 Is the temporal resolution in the acquisition of the input function sufficient for a 
correct estimation of the DA-derived functional parameters? 
 Is the method for correlation between signal intensity and contrast agent 
concentration sufficient, or can it be improved? 
 What would the impact be on the stability and reproducibility of the studied 
parameters if image registration for motion correction was employed? 
 Can pharmacokinetic compartmental modelling be used to assess the hepatic 
kinetics of Gd-EOB-DTPA, and how do they relate to the parameters that have 
already been studied? 
 Could the performance of TSVD be improved with an algorithm to 
automatically determine the optimal truncation threshold c? 
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 How much can the protocol be shortened and how few acquisitions can we 
make and still have acceptable stability in DHCE-MRI derived parameters? 
 Can the spatial or temporal resolution (or both) be improved by using more 
sophisticated pulse sequences? 
 How will the use of a 3T MRI scanner influence the possibilities to improve 
data acquisition in DHCE-MRI? 
 How does total extraction capacity of Gd-EOB-DTPA expressed as HEFml 
correlate to more established ways of quantitative liver function analysis, such 
as ICG clearance or the LiMax test? 
 Can DHCE-MRI be used to assess segmental and total bile flow? 
 
The other main direction regarding future studies will have to deal with the clinical 
usefulness of the method. Several such studies could be performed, for example: 
 
 Can results from DHCE-MRI improve the diagnostic yield of liver biopsies if 
they are directed to segments that seem more affected by disease? 
 Can DHCE-MRI be used to complement and improve the accuracy of currently 
used scoring models in PSC and PBC? 
 Can DHCE-MRI be used to predict which patients with chronic liver disease 
will progress rapidly and develop liver failure, thereby aiding in selection of the 
optimal time-point for liver transplantation? 
 Is there a cut-off value for the predicted post-operative HEFml that will predict 
post-operative liver failure, morbidity or mortality? 
 Can the prospective use of DHCE-MRI decrease postoperative morbidity and 
mortality in liver resections? 
 Can DHCE-MRI be used to monitor the progression of liver damage when neo-
adjuvant chemotherapy is used in the multimodality treatment of colorectal 
cancer liver metastasis? 
 Can DHCE-MRI be used to assess not only the volume increase, but also the 
increase in liver function when portal vein embolisation/ligation is performed? 
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6 CONCLUSIONS 
To conclude, this work presents a method for liver function and volume assessment, 
DHCE-MRI, using MRI for sampling and Gd-EOB-DTPA as tracer. The studies in this 
work have shown that: 
 
 The quantitative parameters HEF, irBF and MTT derived from DA can be 
determined on a global and segmental level in the liver, either using a voxel-
based or ROI-based method. 
 
 TSVD for DA performs marginally better in a computer simulation than FA, 
but in vivo TSVD seems to be substantially inferior to FA in the setting of DA 
and DHCE-MRI. 
 
 Traditional semi-quantitative parameters, such as Cmax, tmax and t1/2 fail in 
separating controls from patients with mild PBC. 
 
 Global HEF and MTT significantly differ between patients with PBC and 
healthy controls. 
 
 The segmental results of the quantitative parameters HEF and irBF correlate 
with downstream biliary obstruction for the corresponding segment in patients 
with PSC. 
 
 Using a voxel-based analysis in DHCE-MRI, total and segmental liver 
extraction capacity of Gd-EOB-DTPA expressed in HEFml can be determined, 
as well as total and segmental liver volumes. 
 
 Total hepatic extraction capacity in HEFml, global median HEF and global 
median MTT differ significantly between healthy controls and patients with 
liver cirrhosis induced by alcohol and/or HCV.  
 
 DHCE-MRI derived quantitative liver function parameters and the LSER show 
good to excellent capacity in separating groups with preserved liver function 
from a group with impaired liver function. 
 
 DHCE-MRI derived quantitative liver function parameters and the LSER 
correlate with established scoring models for chronic liver disease and liver 
cirrhosis. 
 
 In liver cirrhosis and in patients with mild to moderate PSC, liver function is 
significantly more heterogeneously distributed than in healthy controls. 
 
 This heterogeneous distribution of liver function could have significant impact 
on the accuracy regarding prediction of postoperative RLF in patients with 
parenchymal disease. 
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7 SUMMARY IN SWEDISH 
Avhandlingen består av fyra delarbeten, och beskriver en metod där 
magnetkameraundersökning (MR) används för att mäta upptaget av ett kontrastmedel i 
levern. Levern är funktionellt indelad i åtta leversegment med separat blodtillförsel och 
separat gallavflöde. Vid sjukdomar som ger levercirros vet man att sjukdomsgraden 
kan variera mellan olika delar av levern, och det finns idag ingen etablerad metod för 
att bedöma funktionen i de olika segmenten separat.  
 
Sedan några år tillbaka finns ett kontrastmedel för MR, Primovist® (Gd-EOB-DTPA) 
som tas upp av fungerande leverceller, och utsöndras i gallan. Dessa egenskaper hos 
kontrastmedlet har väckt tanken att det skulle kunna användas för bedömning av 
leverfunktionen. Tanken är att om upptaget av Primovist i leverceller kan kvantifieras 
så skulle detta upptag avspegla leverfunktion i det område av levern där upptaget 
studerats. I djurförsök med experimentellt inducerad leverskada har man funnit en med 
MR detekterbar skillnad i upptag av Primovist mellan sjuk och frisk levervävnad. Ett 
antal studier har gjorts på människa där det också kunde konstateras att upptaget av 
Primovist hos leversjuka är lägre än hos friska och att skillnaden ökar med ökande 
sjukdomsgrad. 
 
I det första delarbetet inkluderades 20 friska försökspersoner som undersöktes med MR 
efter att ha erhållit en dos kontrastmedel intravenöst. Kontrasmedelsupptaget i varje 
leversegment kvantifierades genom att signalintensiteten i blodbanan och levern 
registrerades under en sammanlagd tid av 90 minuter. De kurvor över signalintensiteten 
över tid (SI/tid)som erhölls analyserades genom en matematisk modell 
(dekonvoluering). Två olika matematiska metoder användes för dekonvolueringen och 
utfallet av dessa två metoder jämfördes. De parametrar som studerades var 
hepatocytextraktionsfraktionen (HEF) och en pefusionsparmeter (irBF) som beskriver 
lokalt blodflöde i levern. Dessutom genomfördes en datorsimulering där motsvarande 
SI/tid-kurvor försågs med olika mängd störande brus och de två matematiska 
modellernas resultat vid olika signal/brusförhållanden analyserades. Det första 
delarbetets resultat visade att kvantifiering av kontrastmedelsupptag och blodflöde gick 
att göra på segmentnivå i levern, att bägge matematiska metoder gav likvärdiga resultat 
avseende medianvärde på HEF och irBF, men den ena gav lägre standardavvikelse i 
resultaten och bedömdes som en stabilare metod. 
 
I det andra delarbetet undersöktes tolv patienter med primär biliär cirros (PBC) med 
samma MR-metod som de friska försökspersonerna i första delarbetet. Målsättningen 
med studien var att undersöka huruvida upptaget av kontrastmedlet Gd-EOB-DTPA 
skiljde sig åt mellan patienter med leversjukdom och friska försökspersoner, och om 
denna skillnad gick att kvantifiera med den i det första delarbetet använda metoden. 
Som kontrollgrupp användes de friska försökspersonerna från första delarbetet. 
Upptaget kvantifierades dels genom samma matematiska modeller som i det första 
arbetet, dels genom traditionella farmakokinetiska parametrar (Cmax, tmax, t1/2). 
Resultaten visade att HEF var signifikant lägre och den genomsnittliga passagetiden för 
konttrasmtedlet (MTT) var signifikant kortare hos de leversjuka, och att skillnaden 
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ökade med ökande sjukdomsgrad. Studien visade också att de traditionella 
farmakokinetiska parametrarna inte kunda användas för att skilja grupperna åt. 
 
I det tredje delarbetet inkluderades 12 patienter med primär skleroserande kolangit 
(PSC) som undersöktes på samma sätt som försökspersonerna och patienterna i 
delarbete ett och två. Sjukdomen PSC drabbar gallgångarna och leder till 
gallgångsskrumpning (gallgångsstriktur), och vid avancerad sjukdom även skrumplever 
(cirros). Kontrollgruppen var även här försökspersonerna från den första studien. 
Målsättningen var att mäta segmentell och total levervolym med utgångspunkt i 
bildmaterialet. Genom att använda metoden från de två första delarbetena med 
skillnanden att beräkningarna genomfördes i varje voxel (bildmaterialets minsta 
beståndsdelar) separat kunde varje segments och hela leverns extraktionsförmåga 
beräknas. Även information om funktionella aspekter av levervävnaden i övrigt, såsom 
HEF, irBF och MTT, kunde beräknas. Studien visade att resultaten av den totala 
leverfunktionsbedömningen korrelerade med sjukdomsgrad hos patienterna och att den 
segmentella funktionen korrelerade med graden av gallgångsskrumpning. Studien 
visade även att leverfunktionen var betydligt mer ojämnt fördelad inom levern hos 
patienter med PSC jämfört med friska försökspersoner. 
 
Det fjärde delarbetet syftade till att undersöka om de skillnader i total leverfunktion 
som borde finnas mellan friska och leversjuka går att detektera och kvantifiera med den 
i delarbete tre använda metoden. Syftet var också att undersöka om leverfunktionen 
även hos patienter med cirros är oregelbundet fördelat i levern, och vad detta skulle 
kunna innebära vid en leveroperation. I denna studie undersöktes 10 patienter med 
olika grad av levercirros. Även i detta arbete undersöktes total och segmentell 
leverfunktion och samma kontrollgrupp som i tidigare arbeten fick tjäna som referens. 
Resultaten visade att leverfunktionen även hos cirrospatienter är mer ojämnt fördelad i 
levern än hos friska, och att den förväntade skillnaden i leverfunktion gick att detektera 
och kvantifiera. Den totala leverfunktionen mätt som den totala extraktionskapaciteten 
av Gd-EOB-DTPA för hela levern korrelerade väl med etablerade scoringsystem för 
leversjukdom. Studien visade också att den ojämna fördelningen av funktion i levern 
som kan ses vid leversjukdomar kan ha en avgörande betydelse vid leveroperationer, då 
den förväntade kvarvarande funktionen inte kan beräknas på ett tillförlitligt sätt om inte 
regionala skillnader i leverfunktion tas med i kalkylen. 
 
En metod för bedömning av segmentell leverfunktion skulle kunna komplettera de 
nuvarande överlevnadsmodellerna för PSC och PBC, och leverbiopsier skulle kunna 
riktas mot de mest angripna delarna av levern och därigenom ge bättre information om 
sjukdomsgrad. En funktionell bedömning av gallgångsstrikturer hos patienter med PSC 
skulle kunna visa vilka strikturer som är mest lämpade för endoskopisk behandling och 
dessutom utvärdera resultatet av sådan behandling. Även effekten av medicinsk 
behandling och nya medicinska metoder skulle kunna bedömas på ett objektivt sätt. I 
en förlängning skulle en fungerande metod för bedömning av segmentell leverfunktion 
erbjuda en ny möjlighet att följa leverfunktionen över tid under till exempel 
cytostatikabehandling inför kirurgi, underlätta planeringen av leverresektioner och göra 
dessa säkrare, samt följa leverfunktionen hos levertransplanterade. 
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